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SUMMARY
Clinically described for over a century, sickle cell disease is a genetic disorder af-
fecting 100,000 people in the US and millions worldwide. While the mutation only
affects a single protein (hemoglobin) that is expressed in a single cell type (red blood
cells), sickle cell disease has devastating effects throughout the body, significantly
reducing the lifespan of those afflicted. One significant comorbid condition is the
200-fold increase in stroke risk in children under the age of 20, with the highest risk
between 2 and 5 years of age. Although clinicians have demonstrated that the in-
creased stroke risk is attributed to severe remodeling of the cerebral arteries, the
underlying cause of this remodeling remains unknown. In fact, the only treatment
option available for children with sickle cell disease is monthly blood transfusions,
which carries life-threatening risks for alloimmunity and iron overload. Therefore,
there is a clear need to develop a more complete, mechanistic understanding of stroke
in sickle cell disease. To address this need, my research investigates the unique cir-
culatory environment of sickle cell disease and mechanisms promoting rapid arterial
remodeling leading to stroke.
Clinical descriptions of the remodeled cerebral arteries in patients with sickle cell
disease reveal elastin degradation, neointimal formation, and luminal narrowing. Such
arterial remodeling exhibits similarities to other cardiovascular diseases, including
atherosclerosis, which are characterized by changes in vessel structure, concomitant
with protease-mediated remodeling of the extracellular matrix (Platt et al. Am J
Physiol Heart Circ Physiol. 2007). Of particular interest are the cathepsins K and V,
powerful enzymes that degrade collagen and elastin. In order to study the proteolytic
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response in sickle cell disease, our lab developed the multiplex cathepsin zymography
technology, which quantifies of the activity of multiple enzymes with high specificity
and sensitivity (Li et al. Anal Biochem 2010 & Wilder et al. Arch Biochem Biophys
2011).
We have demonstrated that the inflammatory cytokine TNFα is sufficient to in-
crease the activity of cathepsins K and V in endothelial cells (Keegan et al. Mol Cell
Biochem. 2012). This is particularly relevant because sickle cell disease presents as
a chronic inflammatory syndrome, with a 20-fold increase in serum TNFα (Keegan
et al. Anemia. 2012). Therefore, the vasculature in sickle cell disease may be pre-
conditioned by the circulatory milieu to induce cathepsin-mediated remodeling. The
predisposition for remodeling is also aggravated by circulating monocytes in sickle cell
disease; these monocytes exhibit the unique ability to induce cathepsin K activity in
endothelial cells, independent of TNFα (Keegan et al. Anemia. 2012). Together,
these findings indicate that the circulatory environment of sickle cell disease contains
powerful, pro-cathepsin activation factors, which may be responsible for the degree
and speed of remodeling in the cerebral vasculature.
Cathepsins K and V are also sensitive to changes in vascular hemodynamics.
In healthy individuals, pro-remodeling shear stress is generally restricted to regions
where arteries bifurcate; however, in sickle cell disease, aggregations of red and
white blood cells can spontaneously form throughout the vascular tree and impede
blood flow, leading to spontaneous, localized regions of pro-remodeling shear stress.
Through the implementation of a custom shear stress bioreactor, we determined that
endothelial cells exposed to oscillatory, pro-remodeling shear stress significantly in-
crease cathepsin K activity, independent of TNFα activity (Keegan et al. in prep).
Conversely, unidirectional, vasoprotective shear stress reduced cathepsin K activity
below detectable levels, even after stimulation with TNFα. Therefore, the propensity
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for spontaneous perturbation of vascular hemodynamics in sickle cell disease exacer-
bates the already profound risk for cathepsin-mediated remodeling.
To more mechanistically uncover the biochemical pathways regulating the cathep-
sin response to shear stress, monocyte adhesion and TNFα stimulation, we examined
the phosphorylation state of several intracellular kinases. Of several kinases assayed,
the phosphorylated isoforms of JNK and its downstream target c-Jun were signifi-
cantly increased, suggesting a role for the MAPK pathway in mediating cathepsin
activity under inflammatory stimuli. The MAPK pathway was further implicated
when inhibition of JNK signaling significantly reduced (45-65%) cathepsin K and V
activity after TNFα or sickle mononuclear cell stimulation (Keegan et al. Anemia
2012). Interestingly, despite their effects on cathepsin activity, neither vasoprotec-
tive nor pro-remodeling shear stress induced changes in the phosphorylation of JNK
or c-Jun, suggesting divergent biochemical and biomechanical pathways regulating
remodeling responses in sickle cell disease (Keegan et al. in prep).
Our studies have identified constituents of the MAPK/JNK pathway as druggable
targets for the prevention of stroke in sickle cell disease. Therefore, we have employed
a transgenic mouse model that expresses human sickle hemoglobin, thus recapitulating
the multi-faceted pathology of sickle cell disease, including the first identification of
stroke lesions (Keegan et al. in prep). Primary cerebral cells from sickle transgenic
mice also exhibited higher levels of cathepsin activity, compared to wild type controls.
The cerebral and carotid arteries of sickle transgenic animals displayed evidence of
significant elastin fragmentation and remodeling which co-localized with increased
cathespin K expression within the arterial wall; in vivo inhibition of JNK substantially
reduced this expression as well as decreased the number of elastin breaks in the elastic
lamina. Ongoing work aims to conduct additional drug trials to specifically inhibit
active cathepsin, with the hypothesis that specific targeting of cathespin K activity
will prevent the vasculopathy associated with sickle cell diseas thereby reducing the
xxv
risk of stroke.
The etiology of stroke in sickle cell disease is complex, resulting from a ”perfect
storm” of individual biological, biochemical, and biomechanical factors capable of
uniquely and synergistically promoting cathepsin activity. Together, this project has
established a robust, mechanistic, and multi-scale approach for studying remodeling
in response to physical and chemical stimuli, in vitro and in vivo, which will ultimately
enable the development of novel, targeted therapeutics for sickle cell disease, as well




Sickle cell disease (SCD) is a genetic disorder that causes polymerization of hemoglobin
molecules within red blood cells, deforming them into the canonically described
”sickle” shape, resulting in a 220-fold increase in the risk of stroke for children under
the age of 16. Seminal studies have concluded that increased blood velocities in the
middle cerebral artery (MCA) of children with sickle cell disease strongly correlated
to an increased risk for stroke lesion formation. These lesions show advanced arterial
remodeling, characterized by changes in extracellular matrix composition, cell orga-
nization, and cell phenotypes that induce chronic effects on the structure, mechanical
properties, and overall vessel health; however, the underlying mechanisms govern-
ing this process remain unknown. Traditionally, studies of sickle cell cardiovascular
pathologies are limited to low shear, low oxygen, venous-side capillaries. However,
stroke in sickle cell disease originates in large, well-oxygenated arteries exposed to
high shear stress. Endothelial cells normally maintain arterial homeostasis, but in
pathological states they respond to monocyte adhesion, inflammatory cytokines, and
low and oscillatory fluid shear stress. In response, endothelial cells promote mal-
adaptive remodeling of the artery, leading to luminal narrowing and restricted blood
flow. One way this is accomplished is by increasing secretion of cathepsins, power-
ful cysteine proteases, and downregulation of protease inhibitors. Two cathepsins,
cathepsins K and V, are increased during arterial remodeling, and represent the most
powerful elastase and collagenase, respectively, yet identified. In sickle cell disease,
pro-remodeling stimuli, including chronically elevated plasma levels of tumor necro-
sis factor alpha (TNFα), cause systemic activation of the endothelium and induce
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monocyte adhesion. Simultaneously, aggregations of rigid, sickled red blood cells
spontaneously form along the endothelium, disturbing flow and inducing low or os-
cillatory fluid shear stress. Alterations in hemodynamic shear stress due to these
aggregations potentially occur throughout the vascular tree, rather than being lim-
ited to regions near branches or bifurcations, as seen in individuals without sickle cell
disease.
The objective of this proposal is to develop a mechanistic understanding of how the
sickle mutation induces a cardiovascular syndrome that promotes arterial remodel-
ing. The central hypothesis is that disturbed flow, chronic inflammation, and elevated
monocyte adhesion due to sickle cell disease increase cathepsin-mediated arterial re-
modeling contributing to increased risk for stroke. The central hypothesis will be
tested through following aims (Fig 1-1):
Specific Aim 1: Determine the combinatory effects of TNFα stimula-
tion and monocyte adhesion on large artery endothelial cell (EC) cathepsin
activity. Hypothesis: Monocyte adhesion and TNFα stimulation will induce cathep-
sin activity in large artery endothelial cells. People with sickle cell disease have
increased numbers of circulating monocytes and chronically elevated plasma levels
of TNFα. We will investigate how these inflammatory mediators independently and
co-operatively increase cathepsin activity in large artery endothelial cells. EC cul-
tures will be maintained with or without TNFα, as well as co-cultured with primary
monocytes isolated from whole blood of individuals with either normal (AA) or sickle
(SS) β-globin. This study will allow us to parse out critical stimulators of cathepsin
activity, as well as the intracellular signaling cascade that transduce extracellular, in-
flammatory signals circulating in the blood milieu of sickle cell disease into increased
cathepsin production.
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Specific Aim 2: Examine the extent to which low or oscillatory shear
stress observed in sickle cell disease exacerbates cathepsin activity induced
by inflammatory factors and monocyte-endothelial cell interactions. Hy-
pothesis: Low or oscillatory shear stress characteristic of arterial stenosis in sickle
cell disease will promote greater amount of monocyte adhesion and cathepsin activity
compared to unidirectional shear stress. In sickle cell disease, disruption of cerebral
blood flow profiles may accelerat arterial remodeling by upregulating cathepsin activ-
ity, which have been shown to be shear regulated, leading to stroke lesion formation.
Large artery endothelial cells will be stimulated with or without TNFα, as well as
co-cultured with primary monocytes isolated from AA or SS individuals and placed
in a cone-and-plate shear system, which will impart either pulsatile, unidirectional
shear stress characteristic of a normal cardiac cycle, or low or oscillatory shear stress
characteristic of arterial narrowing in sickle cell disease. This study aims to elucidate
how the superposition of low or oscillatory shear stress on the underlying biochemi-
cal and cell-cell interactions in sickle cell disease increase cathepsin activity in large
artery endothelial cells.
Specific Aim 3: Investigate the role of the JNK/c-jun signaling axis
in cathepsin-mediated arterial remodeling and stroke lesion formation in
sickle transgenic mice. Hypothesis: Inhibition of JNK and c-jun singling in sickle
transgenic mice will reduce in vivo cathepsin K and V activities, thereby preserv-
ing structural integrity of cerebral and carotid arteries and reducing the incidence
of stroke. The sickle transgenic mice used in this study have been genetically mod-
ified to exclusively express human hemoglobin, specifically normal or sickle human
β-globin, thereby effectively recapitulating the multifactorial sequelae observed in hu-
man patients. Transgenic mice will be treated with or without an inhibitor of JNK
activity for 8 weeks. Animal brains will be isolated and imaged using a 9T animal
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Figure 1-1: Research aims schematic overview
MRI system to identify and quantify sites of stroke lesions. Subsequently, cathepsin
activity and fragmentation of the elastic lamina of the internal carotid and middle
cerebral arteries will be quantified from these animals, compared to vehicle treated
controls. This study aims to specifically determine the influence of the JNK/c-jun
axis on cathepsin-mediated arterial remodeling leading to stroke in sickle cell disease.
This proposal is innovative because it seeks to elucidate a currently unknown
fundamental, mechanistic understanding of the initiation and progression of large
artery remodeling in sickle cell disease. Currently, there are limited treatment options
available to detect, prevent, or mitigate the development of lethal cardiovascular
pathologies. However, this proposed work aims to analyze the potential of biochemical
and biomechanical factors characteristic to sickle cell disease to induce remodeling of
large arteries, and identify novel, therapeutic targets to improve the quality of life of





Sickle cell disease affects nearly 100,000 people in the United States, and millions
more across the globe. Of the multitude of pathologies and syndromes associated
with sickle cell disease, perhaps one of the more devastating is the development of
stroke in young children. By the age of 20, 11% of children suffering from sickle cell
disease will suffer a major, clinically aparent stroke [97]. A further 17% to 35% of
affected children will suffer an asymptomatic, silent, infarcts that can result in cog-
nitive defects and learning disabilities later in life [94, 107, 125, 144]. Additionally,
the risk of first stroke is highest during the first decade of life, specifically between
the ages of 2 and 5 years [97, 133, 35]. Pioneering work done by the Stroke Pre-
vention Trial in Sickle Cell Anemia (STOP) has shown that elevated middle cerebral
blood flow velocities greater than 200 cm/sec are highly predictive of stroke risk,
which can be mitigated with monthly blood transfusions [2, 4]. Unfortunately, regu-
lar monitoring of cerebral blood flow remains difficult at the clinical level, and regular
blood transfusions carry significant risks of infection, alloimmunity, and iron overload
[143, 133, 4]. Additionally, hydroxyurea remains the only approved drug specifically
approved by the FDA for the management and mitigation of symptoms associated
with sickle cell disease, yet has been shown to be ineffective with reduction of risk of
stroke [39, 130, 145]. Therefore, there is a pressing need for improved for long-term
screening and/or treatment of stroke in sickle cell disease.
One of the complicating factors in developing novel therapeutics and diagnostic
technologies is the lack of a mechanistic understanding of stroke lesion formation or
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progression. Magnetic resonence angiograms of stroke victims with sickle cell disease
showed substantial reduction of blood perfusion through the carotid and middle cere-
bral arteries. Furthermore, the vascular occlusions were shown to be the result of
luminal narrowing due to advanced arterial remodeling, characterized by neoimtimal
formation due to proliferation of endothelial and smooth muscle cells, monocyte in-
filtration, excess matrix deposition, and elastic lamina degradation. The remaining
luminal area becomes further occluded due to aggregations of circulating mononu-
clear cells, red blood cells, and activated platelets [153, 133, 113]. While there are
several working hypotheses describing the luminal aggregation of circulating blood
cells, arterial remodeling in the context of sickle cell disease remains understudied.
The research presented here is significant because it aims to develop a mechanistic
understanding of how the inflammatory circulatory environment unique to sickle cell
disease promotes rapid remodeling of large arteries, in order to identify new thera-
peutic targets for the prevention of stroke lesion formation.
2.2 Sickle Cell Disease
2.2.1 Molecular Basis
Sickle cell disease is a genetic condition that is caused by substitution of valine for
glutamic acid in the sixth position of β-globin, a constituent protein of hemoglobin
protein [57]. While glutamic acid is a polar, hydrophilic molecule, valine is nonpo-
lar and strongly hydrophobic. When saturated with oxygen, the valine residue is
shielded from the aqueous cytoplasm of the red blood cells allowing the hemoglobin
molecules to remain soluble. However, deoxygenation caused by gas exchange within
the microcirculation results in conformational changes in the sickle hemoglobin (HbS)
molecules which expose the hydrophobic residues to the aqueous cytoplasm [11]. Hy-
drophobic interactions between the HbS molecules, governed by overall hemoglobin
concentration, result in the formation of rigid fibers within the red blood cell [54, 24].
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Through heterogeneous nucleation, valine residues along the surface of these fibers
act as focal points for further nucleation and growth of adjacent fibers [38]. As these
fibers grow, they distort the red blood cell membrane resulting in the canonically
described ”sickle” shape. As the red blood cell becomes re-oxygenated, the poly-
merization reaction is reversed; the hemoglobin fibers ”melt” as oxygen is taken up
by the HbS and the normal discoid shape returns. However, the time required to
melt sickled hemoglobin polymers is greater than the time an average red blood cell
spends in oxygenated circulation, which allows for a significant population of sickled
red blood cells to exist in the arterial circulation [95].
One of the more well-characterized presentation of sickle cell disease is the vaso-
occlusive, or pain, crisis. Normally, the bi-concave discoid shape, excess plasma
membrane, and lack of a rigid nucleus allows red blood cells to be highly deformable
thereby permitting them to pass through the microcirculation [123]. However, the
formation of the HbS fibers in sickle red blood cells during gas exchange negates this
capacity for extreme deformation. As a result, sickled red blood cells can become
trapped in the microcirculation restricting or blocking blood flow. The etiology of
sickle cell vaso-occlusion begins with the heterogeneity of the red blood cell popula-
tion. Sickle red blood cells exist in four distinct fractions, with the more immature
cells, reticulocytes, being the most adherent [64, 62]. As sickled reticulocytes begin
accumulating along the endothelium, larger, less deformable cells, such as circulating
monocytes, become entrapped. The resulting cell aggregation further restricts blood
flow until complete occlusion is achieved [65, 40]. Although classically described in
the microcirculation, pathological RBC adhesion to vascular endothelial cells can po-
tentially occur throughout vascular system. One of the significant causes of these
vascular occlusions originates with the pathological interactions between circulating
RBCs and other vascular cells.
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2.2.2 Chronic Inflammation as a Co-Morbidity of Sickle Cell Disease
Although sickle cell disease is canonically classified as a genetic hematological disor-
der, the associated complications that arise from pathological interactions between
RBCs, vascular endothelial cells, and circulating mononuclear cells results in a chronic
inflammatory state, evidenced by the abnormal presence of circulating endothelial cell
adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1), and E-selectin in the plasma [14], as well as ele-
vated plasma levels of inflammatory cytokines like TNFα and IL-1 [104, 86]. Direct
interactions between RBCs and circulating monocytes results in monocytes acquir-
ing an activated phenotype, as shown by the expression of activated integrins [82],
and cytokine-inducible CD64 [36], by increased release of leukocyte elastase, and by
increased shedding of L-selectin and CD16 [75, 14, 153]. The perpetual activated
phenotype of the monocytes, increase in circulating monocyte numbers, and elevated
circulating inflammatory cytokines results in a chronically activated endothelium that
promotes pathological monocyte-endothelial cell interactions. Such interactions are
also independently exacerbated via direct interactions between endothelial cells and
sickle RBCs. Cyclic sickling of the RBC membrane causes membrane inversion, lead-
ing to pathological adhesion to endothelial cells [11], especially among the immature
reticulocytes, which damages the endothelium [14] causing elevated EC expression of
VCAM-1, ICAM-1, P-selectin, and E-selectin [46, 64, 22]. Ultimately, the circulatory
milieu of people with sickle cell disease maintains a chronic activation of endothelium
throughout the vascular tree and promotes monocyte-EC interactions which repre-
sents an initial stage in many pathological vascular remodeling pathologies.
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2.3 Stroke in Sickle Cell Disease
2.3.1 Prevalence of stroke in SCD
While the vaso-occlusive crises of the microvasculature represent a significant co-
morbidity associated with sickle cell disease, aggregations of red blood cells, alone,
are insufficient to explain the clinical reality that children with sickle cell disease
have a 221-fold increase in stroke risk and a 410-fold increase in cerebral infarction
specifically; the risk of first stroke is highest during the first decade of life, specifically
between the ages of 2 and 5 years [97, 133, 35]. In addition to the devastating strokes
with clinically detectable symptoms, 17% to 35% children with sickle cell disease
also suffer from numerous silent, or unsystematic strokes [94, 107, 125], resulting in
cognitive defects and learning disabilities that are undetected until later in the child’s
development [144]. Additionally, children that have had previous silent infarcts are
at higher risk of future strokes in terms of both covert and silent cerebrovascular
events [94, 92]. The risk factors for silent infarction are generally different from those
for clinical stroke with the only identified laboratory predictors being raised white
blood-cell count and the SEN βglobin haplotype [69].
2.3.2 Characteristics of stroke lesion formation
Autopsies and angiographs in the 1970s and 1980s of patients with SCD who died
or suffered clinically presenting strokes showed narrowing, and sometimes complete
occlusion, of the large cerebral arteries that was associated with intimal hyperplasia
[19, 53, 47, 120, 127, 53]. The regions of luminal narrowing often had thickening
caused by fibrous connective tissue and smooth muscle cell proliferation with redu-
plication and fraying of the internal elastic lamina [138]. As mentioned previously,
people with sickle cell disease are also at elevated risk of silent strokes, which are
likely caused by ischemic changes of the frontal lobes, which do not cause motor or
sensory deficits. However, the majority of patients with silent stroke have normal
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large vessel histology and angiography, yet had multiple sites of small vessel disease
resulting in focal areas of necrosis and/or hemorrhage [107, 19]. While the histo-
logical examinations of stroke formation have been previously investigated, there is
a pressing need to more completely underestand the cellular and systemic mecha-
nisms that initiate and regulate progression of vascular lesions leading to stroke in
sickle cell disease. However, recent studies have identified a possible, positive feed-
back loop, that may predispose the large cerebral vessels to stroke lesion formation.
The endothelium of the cerebral vasculature exists in a perpetually activated state
in response to elevated circulating inflammatory cytokines, which, in turn, promotes
adhesion of circulating monocytes and RBCs [133, 53, 153]. Simultaneously, cyclic
sickling of erythrocytes causes hemolysis, in which damaged red blood cells release
hemoglobin into the blood, and its reactive heme group scavenges nitric oxide (NO),
inhibiting flow-mediated vasodilation and exacerbating the luminal narrowing [133].
The byproducts of hemolysis and inflammation act to positively feedback increasing
systemic levels of inflammatory cytokines, monocyte mobilization, and pathologi-
cal monocyte-endothelial [30, 133, 10]. However, the chronic inflammation, elevated
monocyte-endothelial interactions, and elastin fragmentation clinically described in
people with sickle cell disease are similar to what has been observed during other
cardiovascular remodeling pathologies, such as atherosclerotic plaque development.
Therefore, it is plausible that that common mechanisms for arterial remodeling may
exist between the well-studied, well-characterized atherosclerosis and the understud-
ied mechanisms of strokes in children with sickle cell disease.
2.3.3 Treatment options and limitations
While it is difficult for doctors to provide early detection of stroke in sickle cell
disease, seminal work by Adams et al. as part of the Stroke Prevention Trial in
Sickle Cell Anemia (STOP) established the gold-standard for clinical evaluation of
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stroke risk in sickle cell disease by statistically linking cerebral blood flow velocities
greater than 200 cm/s to high stroke risk, as well as establishing monthly blood
transfusions as an effective prophylactic against lesion formation[4]. Transfusions
also result in reductions in middle cerebral artery velocities correlated with the pre-
transfusion velocity [142]. In fact, that the progression of large-vessel stenoses can
be curtailed by transfusion therapy has been corroborated through angiography [120,
133]. It is predicted that children who receive monthly blood transfusions have a
95% of remaining stroke free [106, 4]. However, monthly blood transfusions carry a
significant risk of alloimmunity and iron overload, which preclude this treatment from
being widely deployed across the general population of pediatric sickle cell patients
[143, 133, 4].
2.4 Cathepsins and Arterial Remodeling
2.4.1 Cathepsin overview
Cathepsins, generally known as lysosomal cysteine proteases, are normally described
to degrade intracellular or endocytosed proteins [141, 139, 140]. However, these
proteins have recently been shown to be induced and secreted into the extracellu-
lar spaces, where they participate in pathological tissue remodeling in inflammatory
and autoimmune diseases such as atherosclerosis [121, 129, 81, 58, 99, 131], obesity
[149, 148, 134], rheumatoid arthritis [55, 8], cardiac repair [131], cardiomyopathy
[128, 108, 124], and cancer [93, 29]. Cathepsins are synthesized as precursors that are
enzymatically inactive; removal of the N-terminal propeptide by other proteinases or
autocatalysis allows for exposure of the cathepsin active site allowing for substrate
catalysis [72]. Cathepsins have broad substrate specificity for cell matrix components,
and through the combination of different species, they can degrade nearly all intra and
extracellular proteins. While highly active and extremely potent, cathepsin activity
is tightly regulated extracellularly by cystatin C, which is found in all extracellular
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fluids [34].
2.4.2 Cathepsins in arterial remodeling
For the purposes of this thesis, arterial remodeling will be defined as changes in the
composition of proteins, cell types, and even cell phenotypes that induce chronic ef-
fects on the structure, mechanical properties, and total health of a vessel [98, 81]. This
includes degradation of old matrix by newly activated proteases as well as synthesis
and deposition of new extracellular matrix proteins. Cathepsins have been shown to
be highly active at extracellular matrix degradation, in a variety of tissue remodeling
pathologies. As discussed previously, arterial remodeling in atherosclerotic plaques
shows strong parallels in structure and pathology to stroke lesions observed in children
with sickle cell disease, although there are key differences. Atherosclerotic plaques
form around excess lipid deposition below the endothelial layer, leading to luminal
narrowing. In sickle cell disease, the ”plaques” are not lipid-laden, and are thought
to develop due to excess extracellular matrix deposition. Cathepsins K and V, the
most powerful mammalian collagenase and elastase, respectively, have recently gained
interest as mediators of vascular remodeling. Both cathepsins K and V have been
identified in atherosclerotic plaques [7, 76] and in neointima following balloon an-
gioplasty [87, 111]. Furthermore, the pathophysiological importance of cathepsin K
in atherosclerosis has been demonstrated in double-knockout mice deficient in both
apolipoprotein E and cathepsin K. In this model, the number and size of atheroscle-
rotic lesions were reduced, and there were fewer breaks in the elastic lamina [129].
Several studies have shown expression of cathepsin K by vascular smooth muscle cells
(SMCs) and macrophages, and their roles in vascular remodeling [147, 76, 4, 111].
Studies with human atherosclerosis samples showed a positive correlation between the
cathepsin K levels in endothelium and atherosclerotic lesion development, providing
supporting evidence for cathepsin K in elastic degradation [111].
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2.4.3 Shear stress regulation of cathepsin activity
It has been well established that high, unidirectional fluid shear stress is critical for
maintaining vascular health. Arteries exposed to low or oscillatory (OS) blood flow
are more likely to develop atherosclerotic lesions, while vasculature exposed to unidi-
rectional (USS) flow are more atheroprotected. Part of this shear-dependent plaque
development may, in a significant part, be attributed to biomechanical regulation of
cathepsin activity. Previous studies have shown that OS increases endothelial cell
cathepsin K mRNA and protein levels and activity compared with USS, suggesting
that cathepsin K is regulated by fluid shear stress [111]. Conversely, USS inhibits
gelatinase and elastase activity in endothelial cells in a cathepsin-dependent manner.
It has also been shown that mouse cathepsin L, the ortholog of human cathepsin V,
partially contributes to the shear-dependent regulation of the extracellular matrix




TUMOR NECROSIS FACTOR ALPHA STIMULATES
CATHEPSIN K AND V ACTIVITY VIA JUXTACRINE
MONOCYTE-ENDOTHELIAL CELL SIGNALING AND
JNK ACTIVATION1
3.1 Introduction
Children with sickle cell disease have an 11% chance of suffering a major stroke by
the age of 16, and pulmonary hypertension represents 20-30% of mortality due to
sickle cell disease in adult patients [85, 143]. Both of these pathologies progress with
severe vascular remodeling, defined as changes in the composition of proteins, cell
types, and even cell phenotypes that induce chronic effects on the structure, me-
chanical properties, and total health of a vessel [13, 79, 88]. Histological studies of
vascular remodeling in people with sickle cell disease have implicated increased mono-
cyte infiltration into the subendothelial space, degradation of the elastic lamina, and
luminal narrowing as contributors to lesion development in the cerebral vasculature
that contributes to sickle strokes [113].
Sickle cell disease is a multi-factorial, genetic disorder that causes in vivo poly-
merization of hemoglobin molecules into rigid fibers within red blood cells, deforming
them in the canonically described ”sickle” shape. This hemoglobin polymerization
is thought to occur under low oxygen, or hypoxic, environments of the postcapil-
lary venules as a consequence of the vaso-occlusion and ischemia [11, 61, 65]. The
1Modified from: Keegan, P. M., Wilder, C. L., & Platt, M. O. (2012). Tumor necrosis factor alpha
stimulates cathepsin K and V activity via juxtacrine monocyte-endothelial cell signaling and JNK
activation. Molecular and Cellular Biochemistry, 367(1-2), 6572. doi:10.1007/s11010-012-1320-0
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formation of the hemoglobin fibers, increases membrane tension and cell stiffness, sig-
nificantly reducing the ability of the red blood cells to traverse the microcirculation
[11]. On average, sickle red blood cells only survive 10 days, compared to the 120
days of normal red blood cells before lysing. During hemolysis, damaged red blood
cells release hemoglobin into the blood, and its reactive heme group scavenges ni-
tric oxide, inhibiting flow-mediated vasodilation and exacerbating luminal narrowing
[133]. Stiff, sickled red blood cells and the byproducts of their hemolysis cause dam-
age and increase systemic levels of inflammatory cytokines, mobilized monocytes [30],
and pathological levels of increased monocyte adhesion to the endothelium [133, 10].
Furthermore, sickled red blood cells can spontaneously form aggregations in both the
venus and arterial circulation, obstructing blood flow and leading to localized areas
of hypoxia [10]. Taken together, the inflammation, monocyte adhesion, and vascular
remodeling seen in sickle cell disease are all steps similar to atherosclerotic plaque
development, suggesting that common mechanisms for arterial remodeling may ex-
ist between the well-studied, well-characterized atherosclerosis and the understudied
mechanisms of strokes in children with sickle cell disease.
In atherosclerosis and other cardiovascular disease, endothelial cells initiate vascu-
lar responses to inflammatory cytokines, such as tumor necrosis factor alpha (TNFα).
Activation of the endothelium results in increased surface expression of cell adhe-
sion molecules and secretion of powerful chemokines essential for the recruitment of
circulating monocytes to the vascular wall [91]. Once adhered, paracrine and jux-
tacrine signaling between monocytes and endothelial cells arrest monocytes along the
endothelium, and permit transmigration to the subendothelial space [14, 132]. Ulti-
mately, these inflammatory signals can initiate cellular programs to promote arterial
remodeling as atherosclerotic plaques progress.
Collagen and elastin are two important extracellular matrix proteins degraded
by cathepsins during atherosclerotic lesion formation [77, 83, 111]. Cathepsins are
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a family of cysteine proteases that have been highly implicated in cardiovascular
disease [80, 83], and endothelial cells contribute to their production and this pathology
[110, 111]. Cathepsins K and V, in particular, have gained attention due to their
potent proteolytic activity. Cathepsin K is both the most potent human collagenase
identified, as well as an extremely powerful elastase [59], and has been shown to
be highly expressed in atherosclerotic lesions [129, 111]. Cathepsin V is the most
powerful mammalian elastase yet identified, and is expressed in human monocyte-
derived macrophages [150]. Studies have shown that the human cathepsin V ortholog,
murine cathepsin L [21, 137], significantly contributes to cardiovascular disease in
mouse models [149, 70]. However, elucidating the contributions of specific cell types
and their stimulation of each other is still an important goal to treat this disease.
In this study, the individual and combinatorial effects of TNFα, heme, and mono-
cyte adhesion, and oxygen level on cathepsin activity by human aortic endothelial
cells was investigated to understand how the unique circulatory environment of sickle
cell disease may induce proteolytic remodeling of the arterial wall leading to stroke.
This was accomplished using multiplex cathepsin zymography, a novel enzymatic ac-
tivity assay developed in our lab to simultaneously quantify cathepsins K, L, S, and V
expression levels of active enzyme [78, 147]. Furthermore, we investigated phospho-
rylation of Akt, extracellular signal-regulated kinase 1 and 2 (ERK, c-Jun N-terminal
kinases (JNK), and c-jun to identify intracellular signaling cascades linking TNFα
stimulation and monocyte binding to increased levels of cathepsins K and V activity




Human aortic endothelial cells (HAECs) (Lonza) were cultured in MCDB medium
131 (Mediatech) containing 10% fetal bovine serum (FBS), 1% L-glutamine, 1% peni-
cillin/streptomycin, and 1% endothelial cell growth serum (ECGS). Human THP-1
acute monocytic leukemia cells (American Type Culture Collection [ATCC]) were cul-
tured in RPMI medium 1640 (Mediatech) containing 10% FBS, 0.05% β-mercaptoethanol,
1% L-glutamine, and 1% penicillin/streptomycin. HAECs were transfected with
cathepsin K overexpression plasmids on the pCMVSport6 background at 50-80%
confluence with Lipofectin (Invitrogen) in OptiMEM according to manufacturer’s
instructions.
3.2.2 Monocyte adhesion and endothelial cell co-cultures
HAECs were preconditioned in the presence or absence of 10 ng/mL recombinant
human TNFα (Invitrogen), 2.5µM heme (Sigma), or both for 4 hours in either nor-
moxic (20% O2) or hypoxic (1% O2) conditions prior to adding 500,000 monocytes/ml.
THP-1 monocytes were allowed to adhere for 45 minutes prior to washing with PBS,
and co-cultures adhered to HAECs were maintained for an additional 20 hours un-
der normoxic or hypoxic oxygen conditions. Indirect co-cultures were generated by
suspending 500,000 monocytes/mL above pre-stimulated HAECs using a transwell
insert with a 0.2m pore size for 20 hours. For JNK inhibition studies, HAECs were
preconditioned with 10 µg/mL of SP6000125 (EMD Biosciences) for one hour prior
to addition of THP-1s and co-culture.
3.2.3 Monocyte cell counts
Prior to co-culture, HAECS were stained with 5µM cell tracker red (Life Technolo-
gies) for 15 minutes followed by 3, 5 minute washes with sterile PBS. Simultaneously,
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THP-1 monocytes were incubated in a 5µM dilution of cell tracker blue (Life Tech-
nologies) for 15 minutes, followed by 3, 5 minute washes. THP-1 monocytes were then
allowed to adhere as described previously, and fluorescent images were taken, and cell
counts were detected using automated segmentation algorithms based upon Otsu
global thresholding within Cell Profiler (Broad Institute). For enhanced contrast,
fluorescent images were pseudocolored such that HAECs appear blue and THP-1
monocytes appear green.
3.2.4 Multiplex cathepsin zymography
Cathepsin zymography was performed as described previously [147]. Determination
of cathepsin V band required incubation in acetate buffer, pH 4. Gels were imaged
using an ImageQuant 4010 system (GE Healthcare). Images were inverted in Adobe
Photoshop and densitometry was performed using Scion Image.
3.2.5 in situ zymography
Co-cultures of HAECs and THP-1s monocytes were prepared as above; after the 20
hour incubation time, cultures were rinsed with PBS and incubated in zymography as-
say buffer (0.1M sodium phosphate buffer, 1mM EDTA, 2mM DTT, pH 6.0) contain-
ing 0.5mM Z-GPR-MβNA (Enzo) and 1mM 5-nitrosalicylic acid (Sigma). To isolate
cathepsin K signal, serine proteases were inhibited with 1mM PMSF (Sigma), matrix
metalloproteinases (MMPs) were inhibited with 10 mM EDTA (Sigma), and cathep-
sin B was inhibited with CA-074 (EMD Biosciences). 5µM of the broad-spectrum
cathepsin inhibitor, E-64 (EMD Biosciences), was added for negative controls. Cul-
tures were incubated for 8 hours, washed, and imaged using a Nikon Ti-E fluorescent
microscope. Fluorescence was quantified by averaging pixel intensity across images
of a given area using ImageJ.
18
3.2.6 Phosphorylated kinase analysis with Bioplex
HAEC or co-culture lysates were prepared according to Bioplex instructions (BioRad),
and beads conjugated with antibodies for phosphorylated Akt, extracellular signal-
regulated kinases 1 and 2 (ERK 1/2), c-Jun NH2-terminal kinase (JNK), and c-Jun
(BioRad) were incubated overnight, followed by labeling with biotinylated secondary
antibodies for 1 hour, then with avidin/streptavidin conjugated with phycoerythrin.
Phosphorylated kinase levels were measured using a BioPlex 200 System (BioRad).
3.2.7 Statistical Analysis
Each experimental condition was repeated with a minimum of three biological repli-
cates and each data point is presented as the mean value and standard error of the
mean. Representative images are shown. Unpaired student t-tests were used to de-
termine statistical significance (*p<0.05) between most experimental groups.
3.3 Results
3.3.1 TNFα, but not heme or hypoxia, increase monocyte adhesion to
endothelial cells
One of the initiating factors of arterial remodeling is the activation of vascular en-
dothelial cells to promote monocyte adhesion. In sickle cell disease, vaso-occlusive
crises create regions of local hypoxia, and increased levels of TNFα and heme are
known to induce endothelial dysfunction. Therefore, we sought to determine how
TNFα, heme, and oxygen levels independently and synergistically induce monocyte
adhesion to endothelial cells. Co-cultures of human aortic endothelial cells (HAECs)
and THP-1 monocytes were generated as previously described. TNFα induced 2.5-3
times more monocytes to adhere to endothelial cell cultures (p≤0.05). Interestingly,
oxygen levels had no significant effect on monocyte adhesion (Fig 3-1). Furthermore,
heme did not significantly increase monocyte adhesion, but instead reduced the po-
tency of TNFα-induced monocyte adhesion, although not significantly suggesting that
19
heme may interfere with ECs ability to respond to inflammatory cytokines (Fig 3-2).
3.3.2 TNFα and monocyte adhesion synergistically induce cathepsins K
and V
To determine how TNFα and heme,individually and cooperatively, regulate cathepsin
activity in large artery endothelial cells, we co-cultured human aortic endothelial cells
(HAECs) with and without TNFα and heme, as previously described. TNFα induced
cathepsin K activity (37kDa) in all conditions regardless or oxygen level and increased
cathepsin V activity (35kDa). Interestingly, heme appeared to slightly decrease the
induction of cathepsin K in normoxic conditions but intensified its activity in hypoxic
conditions (Fig 3-3)
Furthermore, TNFα-stimulated active cathepsin K (37 kDa) in HAECs and HAEC/-
monocyte co-cultures, and also increased cathepsin V expression and activity (35 kDa)
by two-fold (Fig 3-4A; n=3, p<0.05). THP-1 monocytes alone did not stimulate
cathepsin K activity, but co-culture with endothelial cells stimulated a 50% increase
in cathepsin V activity (Fig 3-4A lane 3). TNFα and co-culturing with THP-1 mono-
cytes stimulated a 460% increase in cathepsin V active enzyme compared to HAEC
controls (Fig 3-4A lane 6; n=3, p<0.05).
In order to ascertain if the increased active cathepsin observed in the co-cultures
was mediated by direct monocyte-endothelial cell contacts, paracrine factors, or some
combination of both, we implemented a transwell culture system permitting exchange
of soluble factors between the cell types, while being physically separated by a 0.22
µm pore size filter. Indirect communication between monocytes and endothelial cells
failed to increase cathepsin V activity as high as direct contact cultures; additionally,
there was no detectable cathepsin K activity without TNFα stimulation (Fig 3-4B).
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Figure 3-1: TNFα induces increased monocyte adhesion independent of
environmental oxygen Confluent HAEC cultures were stained with 5µM of cell
tracker red prior to stimulated with or without 10ng/mL TNFα. Cultures were
then maintained in either normoxic (20% O2) or hypoxic (1% O2) conditions for 4
hours, after which cell tracker blue labeled monocytes were added. TNFα induced
significantly higher levels of monocyte adhesion to HAECs, but oxygen level had no
significant effect compared to condition matched controls. Images were pseudocolored
for enhanced contrast. (n=6, § p<0.05, SEM bars shown.)21
Figure 3-2: Heme does not significantly alter monocyte adhesion to large
artery endothelial cells. Confluent HAECs were stained with 5µM cell tracker
red stimulated and stimulated with 2.5µM heme; select cultures were simultaneously
stimulated with 10ng/mL TNFα for 4 hours in either normoxic or hypoxic conditions
prior to monocyte co-culture. Neither heme nor heme in combination with TNFα
significantly increased monocyte adhesion regardless of oxygen level. (n=6, § p<0.05,
SEM bars shown.)
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Figure 3-3: TNFα induces cathepsin K activity in large artery endothelial
cells. Cell lysates were obtained from endothelial cell cultures conditioned with
10ng/mL TNFα, 2.5µM heme, or both in either normoxic (20% O2) or hypoxic (1%
O2). Cathepsin activity as assayed using multiplex gelatin zymography.
3.3.3 TNFα turns on cathepsin K in endothelial cells
To confirm the identity of the TNFα-dependent, 37kDa active band as cathepsin K,
HAECs were transfected with CMVSport6 plasmid with cathepsin K gene to drive
constitutive overexpression. We achieved 25% transfection efficiency as estimated
from parallel transfections with GFP vector with same concentration and protocol
(data not shown). Lysates from transfected HAECs were loaded for zymography in
the same gel as lysates from HAECs stimulated with TNFα or vehicle, and results
are shown in figure 3-5. Transfected HAECs displayed an active band at the same
electrophoretic migration distance as that of HAECs stimulated with TNFα, and with
greater intensity than control cells confirming the 37kDa band as cathepsin K (Fig 3-
5A). Further confirmation was achieved with an exclusionary cathepsin zymography
modification; we previously demonstrated that lowering the pH from 6 to 4 during
overnight incubation selects for cathepsin V activity and reduces the cathepsin K
signal [147]. When incubated at pH 4, the upper 37 kDa band intensity diminished in
the TNFα-stimulated samples, but cathepsin V (35 kDa) signal remained detectable
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Figure 3-4: TNFα and direct monocyte adhesion induced cathepsin K and
V activities in endothelial cell-monocytes co-cultures. Endothelial cells, THP-
1 monocytes, and co-cultures were conditioned with 10 ng/mL TNFα. Monocytes
were allowed to interact either (A) directly (indicated by ”D”), or (B) indirectly,
suspended above in a transwell insert with a 0.2µm pore size (indicated by ”I”). (A)
Cell lysates were collected and loaded for cathepsin zymography. Cathepsin K active
enzyme bands were quantified with densitometry and normalized to HAEC, THP-1,
TNFα samples, and cathepsin V active enzyme bands were normalized to unstimu-
lated endothelial cell controls (n=7, *p<0.05, # represents significant difference from
EC control, SEM bars shown). (B) Lysates from transwell cultures were also collected
and loaded for zymography and active enzyme quantified with densitometry (n=3,
*p<0.05, SEM bars shown).
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under both conditions (Fig 3-5) confirming the upper band as cathepsin K.
Quenched, fluorescent synthetic substrates are commonly used to quantify the ac-
tivity of cathepsin family members in cells and in vitro studies [76, 119, 147], and we
used this method to identify TNFα stimulated cathepsin K activity in situ as increased
fluorescence captured by microscopy. After HAECs were stimulated with TNFα, cul-
ture media was replaced with zymography assay buffer containing the cathepsin K
cleavable substrate Z-GPR-MβNA (5 µM), and fluorescent images were captured. To
select for the cathepsin K activity among other proteases that can cleave this sub-
strate, parallel cultures were inhibited with 5 µM E-64 to block all cathepsin activity
or with a protease inhibitor cocktail (10 µM CA-074, 1 mM phenylmethanesulfonyl
fluoride (PMSF), and 10 mM EDTA to inhibit cathepsin B, serine proteases, and
matrix metalloproteinases, respectively) thereby identifying the residual activity as
cathepsin K. TNFα stimulation increased total fluorescent intensity, and more im-
portantly, the fluorescence due to cathepsin K seen after incubation with the protease
inhibitor cocktail (Fig 3-5C). E-64 incubation significantly reduced fluorescent inten-
sity as expected, as shown in the picture and indicated by the dashed line on the
graph (Fig 3-5C,D).
3.3.4 TNFα stimulation and monocyte interactions with endothelial cells
increased JNK and Akt phosphorylation
Next, the intracellular signal cascades initiated by TNFα and THP-1 monocyte adhe-
sion, which appeared to have increased cathepsin K and V activities, were investigated
at baseline (0 hours), after TNFα stimulation and monocyte binding (4 hours), and
six hours of co-culture (10 hours). Co-cultures were maintained for 6 hours instead
of 20, to shorten the length of time between stimulation and analysis to quantify the
phosphorylated kinase signal before it was quiesced. Cell lysates were analyzed for
phosphorylation of Akt, ERK1/2, JNK, and c-Jun using Bioplex technology. JNK
and its downstream signaling protein substrate, c-Jun showed the greatest activation
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Figure 3-5: TNFα turns on cathepsin K activity in endothelial cells. (A) ECs
were transfected with cathepsin K gene on pCMVSport6 to drive overexpression. Cell
lysates collected from HAECs treated with and without 10 ng/mL TNFα, and ECs
transfected with cathepsin K plasmid were lysed, prepared, and loaded for cathepsin
zymography. (B) Cell lysates collected from HAECs treated with and without 10
ng/mL TNFα were incubated in assay buffer of pH 4 or 6 to observe the disappearance
of the 37 kDa cathepsin K band at pH 4. The cathepsin K bands and TNFα stimulated
bands appeared at the same molecular weight in the zymogram. (C) HAECs were
stimulated with 10 ng/mL TNFα combined with either 10g/mL anti-TNFα antibody,
or isotype controls. Cell lysates were collected and cathepsin activity was assessed
via gelatin zymography. (D) For in situ zymography, endothelial cells treated with
or without 10 ng/mL TNFα were incubated in zymography assay buffer containing
1mM 5-NSA and 0.5 mM Z-GPR-MβNA only or 10mM EDTA, 2mM DTT, 1mM
PMSF, and 10µM CA-074 to select for cathepsin K activity, endothelial cells were
also treated with 5µM E-64 to block all cathepsin activity. (E) Fluorescent images of
cultures were taken and mean fluorescence intensity for total fluorescent signal and
cathepsin K specific cathepsin activity was quantified.
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in response to TNFα stimulation by 2.8 and 5.3 fold, respectively (Fig 3-6, n=3,
p<0.01). Akt phosphorylation was significantly increased by TNFα stimulation and
monocyte binding (Fig 3-6, n=3, p<0.01). There were no changes in ERK 1/2 phos-
phorylation in any condition for all time points measured (Fig 3-6).
JNK inhibition significantly decreased TNFα and THP-1 monocyte induced cathep-
sin K and V activities. Since TNFα stimulation of HAECs increased cathepsin K and
V activities, and JNK and c-Jun were highly activated in response, we next tested
the hypothesis that inhibiting JNK pathway would reduce cathepsin K and V activ-
ity. Endothelial cells were incubated for 1 hour with the JNK inhibitor SP6000125
(10 µM), followed by stimulation with 10 ng/mL TNFα or vehicle for 4 hours, and
co-culture with THP-1 monocytes. Inhibition of JNK significantly reduced cathepsin
K active enzyme by 49% in HAEC cultures stimulated with TNFα and by 39% in
co-cultures stimulated with TNFα (Fig 3-7; n=3, p<0.05). In the absence of TNFα
stimulation, there was no detectable cathepsin K activity. A similar effect was ob-
served for cathepsin V; JNK inhibition reduced TNFα stimulated active cathepsin V
by 60% (n=3, p<0.005) in HAECs, by 27% in co-cultures (n=3, p<0.005), and by
81% in TNFα stimulated co-cultures (n=3, p<0.001) (Fig 3-7).
3.4 Discussion
Increased cathepsin activity has been linked to tissue destructive mechanisms in the
cardiovascular system including atherosclerotic elastic lamina degradation [129, 111],
stent restenosis [23, 42], abdominal aortic aneurysm formation [1], and heart valve
remodeling under hypertensive conditions [110]. The identification of TNFα and
monocyte adhesion as both separate and partnering mediators of cathepsins K and
V activation in endothelial cells via JNK signaling provides new insight into the
initiation of proteolytic remodeling in cardiovascular diseases. While the progression
of arterial remodeling in atherosclerosis is well described, little is known of the initial
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Figure 3-6: TNFα and monocyte interactions increase JNK and Akt phos-
phorylation. Confluent HAECs and co-cultures were pre-conditioned with 10ng/mL
TNFα prior to monocyte adhesion as described earlier. HAEC and co-culture cell
lysates were collected for kinase analysis using the BioPlex 200TM machine that uses
Luminex technology. Kinase lysates were collected prior TNFα stimulation (0 hour),
4 hours post stimulation (4 hours), and then after another 6 hours of co-culture with
monocytes (10 hours). Levels of phosphorylated (A) ERK1/2, Akt, JNK, and c-Jun
were measured and phosphorylated protein signal was normalized to unstimulated
EC control (n=3, *p<0.05, SEM bars shown).
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Figure 3-7: Cathepsins K and V activities induced by THP-1 monocytes
are significantly reduced by JNK inhibition with SP6000125. (A) HAECs
were incubated with or without 10µM of SP6000125 for 1 hour, followed by condition-
ing with TNFα or vehicle for 4 hours. THP-1 monocytes were subsequently added,
non-adhered cells were removed, and co-cultures were maintained for an additional
20 hours. Cell lysates were collected analyzed via cathepsin zymography. (B) Den-
sitometric analysis quantified cathepsin K and cathepsin V activity (n=3, *p<0.05,
SEM bars shown).
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degradation or breaks in elastic lamina that will later result in smooth muscle cell
phenotypic switch and migration into neointimal space to initiate lesion formation.
Here we propose that induction of cathepsin expression and mature, active cathepsins
by monocyte binding to endothelial cells during the earliest steps participates in this
initial elastin proteolysis.
Indirect contact between the two cell types increased cathepsin activity, but direct
monocyte-endothelial cell contact induced even higher levels of active cathepsins K
and V activity, even in the presence of TNFα, suggesting that juxtacrine communica-
tion is involved. Pro-TNFα present on monocyte plasma membranes is proteolytically
cleaved to release the soluble cytokine [50]. Soluble TNFα then binds primarily to
TNFR1 with low affinity for TNFR2, but membrane bound pro-TNFα has greater
affinity for TNFR2 [136]. The direct contact between monocytes and endothelial
cells may place the pro-TNFα on monocyte surfaces in close enough contact to lig-
ate TNFR2 on endothelial cell surfaces, which may be a mechanism to explain the
elevated induction of cathepsin activity with direct vs. indirect contact co-cultures
(Fig 3-4B). Stimulation of either TNFR1 or TNFR2 pathway with soluble TNFα or
pro-TNFα on monocyte surfaces may explain the differential regulation of cathepsins
K and V in these results, but further studies are still needed.
The significant effect of JNK inhibition (Fig 3-7) on reducing cathepsin K and V
activity in the co-cultures and after TNFα stimulation implicates JNK signaling cas-
cade as a potentially successful target for therapeutic intervention. Although JNK in-
hibition has been shown to block ICAM-1 expression [25, 56], our studies did not show
a reduction in monocyte adhesion after culturing with the JNK inhibitor, SP6000125
(data not shown) but did reduce cathepsin activity in response. It was shown previ-
ously that the transcription factor AP-1, comprised of the subunits c-fos and c-Jun,
a target of JNK, stimulates cathepsin K promoter activity in macrophages [100], so
the link shown here between JNK activation downstream of TNFα stimulation and
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cathepsin K and V induction may involve AP-1 as well and further investigation of
these pathways may be informative for reducing proteolysis during cardiovascular
disease progression due to multiple cell types and their heterotypic interactions.
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CHAPTER IV
SICKLE CELL DISEASE ACTIVATES PERIPHERAL
BLOOD MONONUCLEAR CELLS TO INDUCE
CATHEPSINS K AND V ACTIVITY IN ENDOTHELIAL
CELLS1
4.1 Introduction
Sickle cell disease is a genetic disorder that causes in vivo polymerization of hemoglobin
molecules into rigid fibers within red blood cells, deforming them in the canonically
described ”sickle” shape. Rigid, sickled red blood cells and the byproducts of their
hemolysis cause chronic vascular damage and increase systemic levels of inflammatory
cytokines, mobilized mononuclear cells [30], and pathological levels of increased mono-
cyte adhesion to the endothelium [133, 10]. Overall, these pathological inflammatory
conditions and mononuclear cell-endothelial cell interactions may contribute to in-
timal thickening, and lumen narrowing seen in pulmonary hypertension and stroke
lesions of children; pulmonary hypertension is responsible for 20-30% of sickle cell
related deaths in adult patients [85, 143] and 11% of children with sickle cell disease
will suffer from a major stroke by the age of 16.
Development of vascular leasions in sickle cell disease, like those that lead to
stroke in young children, is the result intima-media thickening of the arterial wall
[13, 81, 88]. The arterial remodeling that is observed in sickle cell disease has many
similarities to what has been seen in other cardiovascular remodeling diseases, such
1Modified from: Keegan, P. M., Surapaneni, S., & Platt, M. O. (2012). Sickle cell disease
activates peripheral blood mononuclear cells to induce cathepsins k and v activity in endothelial
cells. Anemia, 2012, 201781. doi:10.1155/2012/201781
32
as atherosclerosis, where mononuclear cell infiltration of the subendothelial space,
degradation of the elastic lamina, and subsequent smooth muscle cell proliferation
mediate lesion progression and luminal narrowing [133]. These similarities suggest
that common mechanisms for arterial remodeling may exist between the well-studied,
well-characterized atherosclerosis and the less understood mechanisms of sickle cell
disease.
Arterial remodeling can be defined as changes in the composition of proteins, cell
types, and even cell phenotypes that induce chronic effects on the structure, mechani-
cal properties, and total health of the artery [14, 13, 88, 81]. This includes degradation
of old matrix by newly activated proteases as well as synthesis and deposition of new
extracellular matrix proteins. Cysteine cathepsins, one such family of proteases up-
regulated in arterial remodeling [14, 13, 112], belong to the papain superfamily of
proteases and contain the most potent human collagenases and elastases [150]. In-
creased cathepsin activity has been linked to tissue destruction in the cardiovascular
system with atherosclerotic elastic lamina degradation [111, 129], stent restenosis
[23, 42], abdominal aortic aneurysm formation[1], and heart valve remodeling under
hypertensive conditions [112].
Two cathepsins in particular have gained significant interest in their role in arterial
remodeling in cardiovascular disease. Cathepsin K is the most potent human collage-
nase yet identified[44], as well as an extremely powerful elastase [59, 26]. Additionally,
cathepsin K has been shown to be highly expressed in atherosclerotic lesions where
it degrades arterial collagen and sub-endothelial elastic lamina [129, 111]. Cathepsin
V is the most powerful mammalian elastase yet identified, and is expressed in human
monocyte-derived macrophages [150]. Studies have shown that the human cathepsin
V homolog, murine cathepsin L [21, 137], significantly contributes to cardiovascular
disease in mouse models [149, 112]. Neither of these two enzymes have been linked
to sickle cell disease induced vascular wall remodeling and pathology.
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In this study, we evaluated the potential involvement of cathepsin-mediated arte-
rial remodeling in sickle cell disease by studying the effects of TNFα stimulation and
adhesion of mononuclear cells isolated from individuals homozygous for the sickle mu-
tation on endothelial cell expression of activated cathepsins K and V. We employed
a novel, multiplex cathepsin zymography technique to simultaneously quantify the
active forms of cathepsins K, L, S, and V in response to the different stimulation
and co-culture conditions [28]. Furthermore, we investigated the phosphorylation of
key kinases to identify intracellular signaling cascades linking TNFα stimulation and
mononuclear cell binding to increased levels of active cathepsins K and V as a pro-
posed model for the unique and accelerated tissue remodeling observed in arteries of
children and adults living with sickle cell disease.
4.2 Methods
4.2.1 Ethical Statement
All protocols were reviewed and approved by the Georgia Institute of Technology
Institutional Review Board, and informed consent was received from all participants.
In the case of minors, assent was provided by parents/guardians.
4.2.2 Culture of Primary Human Aortic Endothelial Cells
Human aortic endothelial cells (HAECs) (Lonza) were cultured in MCDB medium
131 (Mediatech) containing 10% fetal bovine serum (FBS), 1% L-glutamine, 1% peni-
cillin/streptomycin, and 1% endothelial cell growth serum (ECGS). Cells were main-
tained with 5% CO2 at 37◦C.
4.2.3 TNFα ELISA
Whole blood samples were allowed to coagulate for 6 hours, followed by centrifu-
gation at 900g for 30 minutes to remove platelets and cells. The supernatant was
collected and TNFα levels were quantified using an enzyme-linked immunosorbent
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assay (ELISA) specific for soluble, human TNFα (R&D Biosystems). Absorbance
values were recorded using Synergy 4TM (Biotek) at 450nm with correction readings
at 540nm. Quantification of TNFα protein levels was calculated by generating a four
parameter logistic standard curve using Gen5TM software (Biotek).
4.2.4 Peripheral Blood Mononuclear Cell Isolation
Whole blood samples were obtained from males and females homozygous for sickle
(SS) or normal (AA) hemoglobin; patients on hydroxyurea, chronic transfusion, or
that had experienced a recent crisis were excluded from this study. Whole blood sam-
ples were centrifuged against a Ficoll-Paque density gradient (density: 1.077g/mL;
GE Healthcare) for 30 minutes at 2450 rpm to separate the buffy coat layer. After
centrifugation, peripheral blood mononuclear cells (PBMCs) were aspirated, washed
in PBS, and pelleted by centrifugation for 10 minutes. The isolated cells were then
washed with a red blood cell lysis buffer (0.83% ammonium chloride, 0.1% potassium
bicarbonate, and 0.0037% EDTA) for seven minutes to remove any contaminating
RBCs. Cell number and viability were determined using a Vi-Cell (Beckman Coul-
ter).
4.2.5 PBMC Adhesion Assay
HAECs were preconditioned in normal growth media in the presence or absence of
10 ng/mL recombinant human TNFα (Invitrogen) and cultured for 4 hours prior
to the addition of 500,000 PBMCs/ml. Isolated PBMCs were allowed to adhere
for 45 minutes prior to washing three times with PBS, and then co-cultures were
maintained for an additional 20 hours. For JNK inhibition studies, endothelial cells
were preconditioned with 10 µg/mL of SP600125 (EMD Biosciences) for one hour
prior to addition of media containing vehicle, 10 ng/mL TNFα, and/or 10 µg/mL of
SP600125.
35
4.2.6 Phosphorylated Kinase Screening
Cell lysates were prepared per BioPlex Suspension Array SystemTM instructions
(BioRad). Lysates were incubated overnight with fluorescently labeled beads specific
for the phosphorylated forms of Akt (Ser473), extracellular signal-regulated kinases 1
and 2 (Thr202/Tyr204, Thr185/Tyr187), c-Jun NH2-terminal kinase (JNK) (Thr 183
/Tyr 185), and c-Jun (Ser63) (BioRad). The samples were then washed and incubated
with kinase-specific, biotinylated antibodies for 2 hours, followed by treatment with
avidin/streptavidin tagged with phycoerythrin. Phosphorylated kinase levels were
measured using a BioPlex 200 System (BioRad).
4.2.7 Multiplex Cathepsin Zymography
Cathepsin zymography was performed as described previously [78]. Determination of
cathepsin V band required incubation in acetate buffer, pH 4 [147]. Gels were imaged
using an ImageQuant 4010 system (GE Healthcare). Images were inverted in Adobe
Photoshop and densitometry was performed using Scion Image.
4.2.8 Statistical Analysis
Each experimental condition was repeated with a minimum of three biological repli-
cates and each data point is presented as the mean value and standard error of the
mean. Representative images are shown. Unpaired student t-tests were used to de-
termine statistical significance (*p<0.05) between most experimental groups.
4.3 Results
4.3.1 Sickle cell disease preconditions circulating PBMCs to induce cathep-
sin K activity
Whole blood samples were obtained from donors homozygous for normal (AA) or
sickle (SS) hemoglobin. First, an ELISA was run to quantify blood serum levels of
TNFα. SS donors had 5.43 ± 2.3 pg/ml of TNFα compared to 0.3 ± 0.3 pg/ml of
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TNFα in AA controls (n=3 p<0.05), an almost 20-fold increase (Fig 4-1A). TNFα
stimulation of endothelial cells increased the adhesion of AA PBMCs, compared to
unstimulated EC cultures (Fig 4-1B); however, the number of adhered SS PBMCs
was 100 times higher than TNFα stimulated AA PBMC co-cultures (Fig 4-1B; n=3,
p¡0.001). Cells were cultured together for an additional 20 hours for cathepsin in-
duction, prior to lysing, collection, and multiplex cathepsin zymography. SS PBMCs
significantly increased levels of active cathepsins K and V when co-cultured with en-
dothelial cells, and without exogenous TNFα stimulation (Fig 4-1C), suggesting that
the SS PBMCs were preconditioned to induce this activity. AA PBMC co-cultures
in the absence of TNFα lacked detectable bands of active cathepsin K (Fig 4-1C, left
lane).
4.3.2 TNFα stimulation and PBMC interactions with endothelial cells
activate JNK signaling
To investigate the intracellular signaling cascades increasing the levels of active cathep-
sins K and V downstream of TNFα and PBMC adhesion cues, we measured phos-
phorylation of JNK, c-jun, Akt, and ERK1/2 using Bioplex/Luminex technology, a
quantitative bead-based immunofluorescent assay that allowed measurement of all
four signals in one cell extract after 24 hours of co-culture. JNK and its downstream
signaling protein substrate, c-Jun showed the greatest activation in response to TNFα
stimulation with or without AA or SS PBMCs (Fig 4-2A, B, n=3, p<0.01) with c-
Jun activation as high as 6-fold that of the EC controls. Akt phosphorylation was
significantly increased by AA PBMC binding alone even without TNFα stimulation
(Fig 4-2C, n=3, p<0.01). There were no changes in ERK 1/2 phosphorylation in any
condition for all time points measured (Fig 4-2D).
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Figure 4-1: Sickle cell disease preconditions circulating peripheral blood
mononuclear cells to induce cathepsin K activity. Whole blood samples were
obtained from donors homozygous for the normal β-globin allele (AA) and homozy-
gous for the sickle allele (SS). (A) Baseline serum levels of TNFα were quantified
using an ELISA specific for human TNFα (n = 3, *p<0.05, SEM bars shown). (B)
PBMCs were isolated via differential centrifugation through a density gradient. For
co-cultures, confluent EC cultures were preconditioned with 10 ng/mL TNFα for 4
hours, prior to the addition of either AA or SS PBMCs. Nonadherent cells were
washed away, and co-cultures were maintained for an additional 20 hours. Repre-
sentative images of co-cultures were used for mononuclear cell adhesion counts. (C)
Cells were lysed and cathepsin K activity was assessed using multiplex cathepsin
zymography and quantified via densitometry (n = 10, *p<0.05).
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Figure 4-2: TNFα and PBMC interactions increase JNK and Akt phospho-
rylation. Confluent HAECs were cocultured with peripheral blood mononuclear cells
isolated from AA or SS donors, and lysates were collected for kinase analysis. Levels
of phosphorylated (A) JNK, (B) c-Jun, (C) Akt, and (D) ERK1/2 were measured,
and phosphorylated kinase signals were normalized to unstimulated HAEC control
(n = 3,*p<0.05, SEM bars shown).
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4.3.3 Cathepsins K and V activities induced by sickle cell disease PBMCs
were significantly reduced by JNK inhibition
Since JNK and c-jun phosphorylation were significantly upregulated, we tested if in-
hibiting this signal cascade would block the increase in levels of active cathepsins K
and V by endothelial cells after adhesion and co-culture with SS PBMCs. HAECs
were cultured with or without SP600125, a JNK inhibitor, for 1 hour prior to addi-
tion of 10 ng/mL TNFα or vehicle. AA or SS PBMCs were subsequently added, and
non-adhered cells were washed away. Cell lysates were collected after 24 hours, and
cathepsin activity was assessed through multiplex cathepsin zymography. SP600125
significantly reduced the upregulated cathepsin K and cathepsin V activities of un-
stimulated SS PBMCs when co-cultured with endothelial cells by 48% and 29%,
respectively (Fig 4-3; n=5, p<0.05).
4.4 Discussion
Endothelial cell expression of cathepsins and increased cathepsin-mediated elastase
activity are upregulated during atherosclerotic development and induced by inflam-
mation and altered hemodynamics [11, 112, 111, 122, 129] which are both present in
sickle cell disease [11], leading to our hypothesis that elevated TNFα and increased
circulating mononuclear cells would stimulate increased endothelial cell cathepsin ac-
tivity. This elevated activity may contribute to arterial remodeling in sickle cell
disease. The findings of this study specifically implicate TNFα and mononuclear cell
binding to endothelium as key mediators, and that circulating mononuclear cells in
sickle cell disease are predisposed to induce cathepsin proteolytic activity.
Here, we have specifically shown that TNFα stimulation increased the expres-
sion and activity of the most potent mammalian collagenase and elastase, cathepsins
K and V, respectively (Fig 4-1). Additionally, SS PBMCs significantly increased
cathepsin K activity in endothelial cells in the absence of TNFα, suggesting that
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Figure 4-3: Cathepsins K and V activities induced by sickle cell dis-
ease PBMCs are significantly reduced by JNK inhibition with SP600125.
HAECs were incubated with or without 10 µM of the JNK inhibitor, SP600125, 1
hour prior to TNFα stimulation, as described previously. Co-cultures with AA or
SS PBMCs were maintained for an additional 20 hours. Cell lysates were collected
and analyzed via multiplex cathepsin zymography. Densitometric analysis quantified
active cathepsins K and cathepsin V (n = 3, *p< 0.05, SEM bars shown).
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they were preconditioned in the blood for adhesion to endothelium and cathepsin K
induction (Fig 4-1); AA PBMCs required TNFα stimulation to reach these higher
levels of cathepsin K and V (Fig 4-1). These findings are consistent with reports
that circulating sickle erythrocytes increase mononuclear cell activation and adhe-
sion to endothelial cells[153], and support our hypothesis that the blood milieu of
people living with sickle cell disease predisposes circulating mononuclear cells to ad-
here to endothelium and promote arterial remodeling. Previous studies have already
established that the circulatory environment in sickle cell disease preconditions pe-
ripheral blood mononuclear cells into a pathologically activated state, where these
cells produce 139% more TNFα per cell than control mononuclear cells [14, 153];
these mechanisms may be at play here leading to increased active cathepsins K and
V.
Inhibition of JNK signaling with SP600125 reduced the inflammation-induced ac-
tivation of cathepsins K and V in AA and SS PBMC co-cultures with endothelium
(Fig 4-3). These findings highlight the role of JNK signaling as an integration control
point and as a therapeutic target to inhibit the initiation of gene and protein expres-
sion in response to inflammatory stimuli resulting in endothelial cell upregulation of
cathepsins K and V protein and activity. More importantly, the predisposition of SS
PBMCs to induce these effects suggests that these novel mechanisms may be occur-
ring constantly in the vasculature of individuals with sickle cell disease. It will be
important to continue these studies by quantifying cathepsin activation of SS donors
with and without a history of stroke, or coupling these analyses with high transcra-
nial doppler velocity measurements which are known to be a risk factor for stroke, in
order to parse differential activation mechanisms potentially responsible for the in-
creased risk. Such investigations may reveal novel biomarkers relevant to stroke risk
prediction in pediatric patients and open new avenues for pharmaceutical therapies




Elevated inflammatory factors and circulating mononuclear cells inherent to sickle
cell disease induce pathologically high levels of cathepsins K and V activity when
binding to and stimulating endothelial cells, increasing proteolytic activity that may
be involved in arterial wall remodeling to increase risk of stroke and pulmonary hy-
pertension. There is a pressing need for novel pharmaceutical targets to inhibit these
activities, and from this work, we propose that JNK, cathepsin K, and cathepsin V




NFKB AND JNK SIGNALING INTEGRATE
PATHOLOGICAL BIOMECHANICAL AND
INFLAMMATORY SIGNALS TO REGULATE
CATHEPSIN K PROTEOLYTIC ACTIVITY IN AORTIC
ENDOTHELIAL CELLS: IMPLICATIONS FOR CHRONIC
VASCULOPATHY IN SICKLE CELL DISEASE.1
5.1 Introduction
Sickle cell disease is a genetic disorder affecting nearly 100,000 Americans and millions
worldwide. Although commonly regarded as a hematological disorder characterized
by the unique, sickle red blood cells, people with sickle cell disease have an 11%
chance of stroke before the age of 20, with the highest risk between 2 and 5 years old
[10, 2, 115]. Post-mortem examination of the cerebral vasculature of children who
have suffered strokes revealed significant luminal narrowing, as well as delamination
and fragmentation of the internal elastic lamina of the internal carotid and middle
cerebral arteries [133, 53, 116]. Moreover, in contrast to other cardiovascular diseases
in which vascular remodeling develops over decades prior to clinical presentation,
arterial remodeling in children with sickle cell disease progresses at a dramatically
accelerated rate. Despite the high risk and rapid formation of arterial remodeling in
sickle cell disease, there currently exists no mechanistic understanding of how these
1Modified from: Keegan, P. M., Anbazhakan, S., Pace, B.S. & Platt, M. O. NFKB and JNK
signaling integrate pathological biomechanical and inflammatory signals to regulate cathepsin K
proteolytic activity in aortic endothelial cells: implications for chronic vasculopathy in sickle cell
disease. Manuscript in preparation
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vascular lesions form or progress. However, the unique inflammatory and hemody-
namic circulatory environment in sickle cell disease led our group to hypothesize that
pathological proteolytic remodeling may play an important role in vascular lesion
development.
An often overlooked complication associated with sickle cell disease is the perpet-
uation of a chronic inflammatory syndrome characterized by elevated serum levels
of the inflammatory cytokine tumor necrosis factor alpha (TNFα); in fact, people
with sickle cell disease exhibit over 20-fold higher levels of baseline serum TNFα [67].
Additionally, people with sickle cell disease also have highly elevated numbers of cir-
culating monocytes and increased monocyte-endothelial cell interactions throughout
the vascular tree. Both elevated serum levels of TNFα and monocyte-endothelial cell
interactions have been strongly correlated with the initiation and progression of many
cardiovascular diseases characterized by arterial remodeling, such as atherosclerosis
[71, 91]. Work by our group has shown that arterial endothelial cells respond to both
elevated TNFα levels and interactions with sickle white blood cells by activating the
powerful elastase and gelatinase, cathepsin K [68, 67]. Cathepsin K has become of
particular interest in the context of arterial remodeling as it is the most powerful hu-
man collagenase, an extremely potent elastase [59], and has been strongly implicated
in the progression of several cardiovascular diseases such as atherosclerosis [83, 80]
and abdominal aneurisms [81]. In addition to responding to circulating inflammatory
signals, arterial endothelial cells are sensitive to biomechanical signals, such as blood
flow.
Endothelial cells are capable of monitoring and responding to hemodynamic shear
stress, generated by blood flow through a vessel. Alterations in hemodynamic shear
stress stimulate various cellular responses within endothelial cells, resulting in dy-
namic changes to the arterial environment. It is because of the strong mechanosensi-
tive nature of endothelial cells, and their ability to affect not only the function, but
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also structure, of the artery that hemodynamic shear stress represents of the crit-
ical mediators of arterial remodeling diseases [88, 60, 74]. Vessels exposed to high
magnitude, unidirectional shear stress (vasoprotective) statistically are not at risk
for pathological arterial remodeling [152, 49] while vessels exposed to low magnitude,
oscillatory shear stress (pro-remodeling) are at significantly higher risk for arterial
remodeling pathologies [73, 49]. Previous work done by our group and others have
shown that cathepsin K is also shear regulated, with pro-remodeling shear stress
stimulating increased cathepsin K expression and activity [27, 111].
In patients who have suffered a sickle cell related stroke, vascular lesions are com-
monly found in the cerebral and carotid arteries [90, 118, 2, 18, 48]. However, these
arteries may spontaneously develop regions of pro-remodeling shear stress due to ad-
hesion of red and white blood cell aggregations along the arterial wall [11] providing
a second, independent, pro-cathepsin K signal to the vascular wall. Taken together,
the cerebrovasculature of children with sickle cell disease represents a unique amal-
gam of inflammatory and biomechanical factors that, independently, are known to
activate cathepsin K; however, the interplay between TNFα and shear stress reg-
ulation of cathepsin activity in large artery endothelial cells remains unclear. In
this study, we developed an in vitro model to independently and combinatorially as-
sess physiologically relevant stimuli and define a mechanistic pathway by which large
artery endothelial cells simultaneously integrate TNFα stimulation and pathological
hemodynamic shear stress via the JNK and NFκB pathways to regulate cathepsin
expression and enzyme activity.
46
5.2 Methods
5.2.1 Cell Culture and Actuation of Physiological Shear Stress
Human aortic endothelial cells (HAECs) (Lonza) were cultured in MCDB medium
131 (Mediatech) containing 10% fetal bovine serum (FBS), 1% L-glutamine, 1% peni-
cillin/streptomycin, and 1% endothelial cell growth supplement (ECGS) isolated from
bovine cerebral tissue. Vasoprotective and pro-remodeling shear stress profiles were
generated by digitizing physiological the physiological shear stress waveforms recoded
by Dai et al [32, 31]. The vasoprotective waveform, characterized by high, unidirec-
tional wall shear stress was obtained from the distal internal carotid artery as it is
a representative region protected from atherogenesis; conversely, the pro-remodeling
waveform was obtained from the carotid sinus due to it experiencing the highest
degree of low, oscillatory shear stress and being vulneratble to pathological arterial
remodeling. HAECs were grown to confluence in a 10cm dish, and stimulated with or
without 10ng/mL recombinant human TNFα (Invitrogen), then placed into a cone-
and-plate bioreactor, and exposed to vasoprotective or pro-remodeling shear stress
for 20 hours (Appendix A; Fig 5-1). For JNK inhibition studies, confluent HAECs
were stimulated with 10µg/mL of the JNK inhibitor SP6000125 (Invitrogen) for 1
hour prior to treatment with 10ng/mL TNFα. For NFκB inhibition studies, 5µM of
the inhibitor Bay 11-7082 (Sigma) which selectively and irreversibly inhibits NFκB
activation by blocking phosphorylation of IκBα was added to cultures for 1 hour prior
to stimulation with TNFα.
5.2.2 Multiplex Cathepsin Zymography and Western Blot
Cells were lysed using zymography lysis buffer (20 nM TrisHCl [pH 7.5], 5 mM
ethyleneglycoltetraacetic acid [EGTA], 150 mM NaCl, 20 mM β-glycerol phosphate,
10 mMNaF, 1 mM sodium orthovanadate, 1% Triton X-100, and 0.1% Tween 20) with
0.1% leupeptin [78, 147]. To assess cathepsin activity, cell lysates were analyzed using
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Figure 5-1: Physiological vasoprotective and pro-remodeling waveforms ac-
tuated by cone-and-plate bioreactor. Digitization of the time-dependent wall
shear stress functions at the atheroprotected and atheroprone regions of the human
carotid sinus as previously derived by Dai et al.[31]
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multiplex cathepsin zymography, as described previously [78, 147, 67, 68]. Gels were
imaged using an ImageQuant 4010 system (GE Healthcare). Images were inverted
in Adobe Photoshop and densitometry was performed using NIH ImageJ. Western
blotting was used to determine phosphorylated and total c-Jun N-terminal kinase
(JNK); Cell Signaling) and c-jun primary antibodies (Cell Signaling) and secondary
antibodies to be visualized with a LI-COR Odyssey scanner. Densitometry of labeled
nitrocellulose membranes was performed using NIH ImageJ.
5.2.3 Chromatin Immunoprecipitation Assay for Activator Protein 1
Isolation of HAEC genomic DNA for chromatin immunoprecipitation (ChIP) was
completed using the EZ-Chip system (Millipore). Briefly, after isolation of genomic
DNA, and fragmentation via sonication for 5 seconds at 15% amplitude followed by a
10 second rest was repeated 22 times for a total sonication time of 110 seconds. PCR
primers were synthesized based on previously identified using previously identified
binding regions for activator protein 1 (AP-1) on the cathepsins K geneGelb:1997tx.
The forward sequence, 5’-TCCTAACAGGAAAGGGGTAGGA-3’, and the reverse
sequence, 5’-AGACTGTCTTTGGTGGCAAAT-3’, were analyzed using the Basic
Local Alignment Search Tool (BLAST; NIH) to ensure minimal cross reactivity with
other sequences prior to synthesis (Integrated DNA Technologies).
5.2.4 Quantification of cathepsin K mRNA
mRNA was isolated from shear conditioned HAEC cultures using RNeasy mini-
prep (Quiagen) and reverse transcribed to cDNA using the forward primer sequence
5’-ATATGTGGGACAGGAAGAGAGTTGT-3’ and the reverse primer sequence 5’-
GGATCTCTCTGTACCCTCTGCATTT-3’. Quantitative real time PCR was per-
formed and relative cathepsin K mRNA synthesis was quantified using ∆∆Ct
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5.2.5 Immunostaining
As described previously, confluent HAEC cultures were conditioned with 10ng/mL
TNFα, and maintained under static, vasoprotective, or pro-remodeling shear stress for
20 hours. Cells were rinsed with PBS three times, and fixed with 4% paraformalde-
hyde (PFA) for 10 minutes, rinsed with PBS, permeabilized using 0.2% Triton X,
and blocked with 3% BSA in PBS for 1 hour at room temperature. HAECs were
incubated overnight at 4C with monoclonal rabbit anti-cathepsin K (Cell Signaling;
1:100), monoclonal rabbit anti-phosphorylated c-Jun (Cell Signaling; 1:100), or mon-
oclonal rabbit anti-NFkB (Cell Signaling; 1:50). Cells were rinsed three times with
PBS, and then incubated with Alexa Fluor 488 conjugated secondary antibodies (In-
vitrogen; 1:150) for 1h at room temperature. Cultures were counterstained with
Alexa Fluor 568 phalloidin (10µg/mL; Invitrogen), and Hoechst (10mg/mL; Invitro-
gen), mounted, and cover slipped. Images were acquired using a Zeiss LSM 700-405
confocal microscope.
5.2.6 Statistical Analysis
Each experimental condition was repeated with a minimum of three biological repli-
cates and each data point is presented as the mean value and standard error of the
mean (SEM). Representative images are shown. Unpaired student t-tests were used
to determine statistical significance (*p<0.05) between most experimental groups.
5.3 Results
5.3.1 Vasoprotective shear stress is sufficient to reduce the amount of
active cathepsin K in endothelial cells
We first examined the regulation of cathepsin K in response to simultaneous integra-
tion of physiological shear stress with TNFα stimulation in large artery endothelial
cells. HAECs were grown to confluence and stimulated with TNFα and simultane-
ously exposed to either vasoprotective or pro-remodeling shear stress. Pro-remodeling
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shear stress (Fig 5-2 A, Lane 5) induced a 1.5-fold higher level of active cathepsin
K compared to TNFα-stimulated cells cultured in static conditions (Fig 5-2 A, Lane
2); co-stimulation of pro-remodeling shear stress with TNFα did not significantly
increase cathepsin K activity compared to pro-remodeling shear stress alone. Vaso-
protective cultures stimulated with TNFα exhibited a 0.5-fold decrease in cathepsin
K activity (Fig 5-2 A Lanes 4; n=3 p<0.05). Immunocytochemistry staining for intra-
cellular cathepsin K in HAECs indicated that TNFα-stimulation, and pro-remodeling
shear stress both increase protein expression of cathepsin K in HAECs. Conversely,
vasoprotective shear stress reduced staining of intracellular cathepsin K, even in the
presence of TNFα (Fig 5-2B). These findings suggest that biomechanical cues may be
capable of enhancing or repressing the proteolytic response to inflammatory stimuli.
Cystatins are potent physiological inhibitors of cathepsin activity, and are ubiq-
uitously expressed by all cell types in the body. Cystatin B primarily functions to
inhibit intracellular cathepsin activity activity, and while cystatin C primarily in-
hibits extracellular activity, it can be taken up by cells and inhibit cathepsins along
the endocytic pathway. We have so far observed that hemodynamic shear stress signif-
icantly reduces the amount of activate cathepsin K produced by arterial endothelial
cells; therefore we next hypothesized that hemodynamic shear stress may regulate
cathepsin activity through differential expression of cystatin B and C. Cultures were
immunostained for cystatin B protein expression showed no substantive changes in
response to either shear stress or TNFα stimulation, suggesting that the changes in
active cathepsin K levels as a result of either vasoprotective or pro-remodeling shear
stress are not likely due to increased cystatin B-cathepsin K interactions (Fig 5-3).
Additionally, we also investigated the potential for cystatin C to be shear regu-
lated. Immunostaining of sheared HAECs indicated that pro-remodeling shear stress
had markedly increased intracellular cystatin C levels compared to vasoprotective
shear stress (Fig 5-4), which is in apparent opposition to what observed cathepsin
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Figure 5-2: Vasoprotective shear stress reduces TNFα induced cathepsin
K protein and activity. Confluent HAECs were stimulated with 10 ng/mL TNFα,
and subjected to static conditions (lanes 1 & 2), vasoprotective (lanes 3 & 4), or
pro-remodeling (lanes 5 & 6) shear stress for 20 hours, (A) then lysed to quan-
tify cathepsin activity with multiplex cathepsin zymography and densitometry. Pro-
remodeling shear stress alone was sufficient to induce detectable levels of cathepsin
K activity (Lane 5 vs Lane 1); however, co-stimulation with TNFα did not result
in a synergistic effect. Conversely, cultures maintained under vasoprotective shear
stress reduced TNFα-mediated cathepsin K activity by 0.5-fold. * denotes statistical
significance with p<0.05. (B) Alternatively, cells were fixed with 4% paraformalde-
hyde, permeabilized with 0.2% Triton-X, and immunolabeled for cathepsin K protein
(green); cultures were counterstained with phalloidin (red) for actin, and Hoechst
(blue) for nuclei. Baseline cathepsin protein in HAECs was increased in response to
pro-remodeling shear stress, but vasoprotective inhibited this (n=3, representative
images shown). TNFα also stimulated an increase in cathepsin K activity in static
and pro-remodeling conditions, but was substantially reduced vasoprotective cultures
stimulated with TNFα.
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Figure 5-3: HAEC expression of cystatin B is not changed by TNFα and
shear stress stimulation. Confluent HAECs were stimulated with 10ng/mL TNFα,
and sheared with vasoprotective or pro-remodeling hemodynamic waveforms for 20
hours. Cultures were immunostained for expression of cystatin B (green), and coun-
terstained for nuclear DNA (blue), and actin filaments (red) for increased visualization
of the cell body.
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activity in Fig 5-2. However, cystatin C is secreted by cells soon after synthesis
and is likely to inhibit the intracellular cathepsin activity we assay for in this study.
Upregulation of cystatin C under proremodeling shear stress likely serves to protect
the extracellular environment from pathological remodeling caused by upregulated
cathepsin activity.
5.3.2 Physiological Shear Stress Regulates Cathepsin K Activity Inde-
pendently of JNK/c-Jun Signaling
Next, we investigated the intracellular kinase-signaling network that integrates bio-
chemical and biomechanical stimuli. Previously, our group established that TNFα-
dependent activation of cathepsin K activity in large artery endothelial cells is depen-
dent on the JNK/c-jun signaling axis [68]. Based upon the synergistic cathepsin K
activity in response to both biomechanics and TNFα, we then tested the hypothesis
that physiologically relevant shear stress would also modulate JNK and c-Jun phos-
phorylation, leading to changes in cathepsin K expression and activity. As expected,
TNFα alone resulted in 3.3-fold increase in JNK phosphorylation, and a 3.4-fold in-
crease in c-Jun phosphorylation compared to vehicle controls (Fig 5-5; n=3, p<0.05).
Interestingly, despite the previously established increase in cathepsin K activity, JNK
and c-Jun phosphorylation were not significantly increased by pro-remodeling shear
stress alone or in combination with TNFα, compared to static controls (Fig 5-5 C-
D; n=3 p>0.3). Furthermore, while vasoprotective cultures inhibited cathepsin K
activity, they did not significantly decrease phosphorylation of JNK or c-Jun, com-
pared to controls (Fig 5-5 A-B; n=3, p>0.8). Together, these data confirm that the
JNK/c-Jun signaling axis is involved in inflammatory cytokine induction of cathep-
sin K; however, the biomechanical shear stress regulation of proteolytic activity is
independent of JNK/c-Jun, suggesting regulation through a secondary, independent,
mechanism.
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Figure 5-4: Pro-remodeling shear stress increases cystatin C expression
in large artery endothelial cells. HAECs conditioned with pro-remodeling shear
stress had markedly more intense cystatin C signal (green) by immunostaining, com-
pared to cultures maintained under vasoprotective shear stress. Cultures were im-
munostained for expression of cystatin C (green), and counterstained for nuclear
DNA (blue), and actin filaments (red) for increased visualization of the cell body.
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Figure 5-5: TNFα stimulates JNK/c-Jun activation under vasoprotective
and pro-remodeling shear stresses. Confluent HAEC cultures stimulated with
or without 10ng/mL TNFα, and maintained under static, pro-remodeling, or vaso-
protective shear stress were lysed and phosphorylated and total protein levels of JNK
and c-Jun were assessed using Western blot. (A, B) TNFα, alone induces a 3-fold in-
crease in phosphorylation of JNK and c-Jun, relative to total protein levels. However,
vasoprotective shear stress does not significantly alter JNK or c-Jun phosphorylation
levels, regardless of TNFα stimulation. (C, D) Additionally, pro-remodeling shear
stress did not alter JNK or c-Jun phosphorylation levels, relative to vehicle or TNFα
static controls. * denotes p<0.05.
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We also tested the hypothesis that hemodynamic shear stress altered transcrip-
tional regulation of cathepsin K either by altering nuclear localization of phosphory-
lated c-Jun, or preventing binding of phosphorylated c-Jun to the promoter region
of the cathepsin K gene. Immunostaining of sheared endothelial cells indicated that
TNFα induced a substantial increase in phosphorylated c-Jun within the nucleus of
HAECs compared to vehicle, as expected (Fig 5-6 A). Pro-remodeling shear stress
alone also induced translocation of phosphorylated c-Jun compared to static vehicle
cultures, though to a lesser extent compared to that exhibited by TNFα stimulation
(Fig 5-6 A). Consistent with the Western blot results, vasoprotective shear stress did
not reduce TNFα-mediated phosphorylation or nuclear translocation of c-Jun (Fig 5-6
A). Furthermore, quantification of c-Jun binding to the cathepsin K promoter region
indicated that TNFα alone increased binding by 2.7-fold compared to vehicle, and was
not significantly decreased by vasoprotective shear stress. Vasoprotective shear stress
alone increased c-Jun binding by 8.3-fold, and TNFα co-stimulation with vasopro-
tective shear increased c-Jun binding to the cathepsin K promoter region by 28-fold
(Fig 5-6 B; n=4, *p<0.05). However, despite increases in phosphorylated c-Jun bind-
ing to the promoter region of the cathepsin K gene, quantification of cathepsin K
mRNA levels gene activity is significantly reduced under vasoprotective shear stress,
regardless of TNFα stimulation (Fig 5-6 C). Conversely, pro-remodeling shear stress
alone significantly increased cathepsin K gene activity (Fig 5-6 D), corroborating the
immunostaining and zymography data. Therefore, these data confirm that, while
shear stress influences both baseline and TNFα-mediated cathepsin K expression and
activity, the mechanism is independent of the established TNFα-dependent JNK/c-
Jun signaling axis.
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Figure 5-6: Vasoprotective shear stress does not block nuclear localiza-
tion of phosphorylated c-Jun. Confluent HAECs were stimulated with 10ng/mL
TNFα, and subjected to static conditions, vasoprotective, or pro-remodeling shear
stress for 20 hours. (A) Cells were fixed with 4% paraformaldehyde, permeabilized
with 0.2% Triton-X, and immunolabeled for phosphorylated c-Jun (green); cultures
were counterstained with phalloidin (red) for actin, and Hoechst (blue) for nuclei.
No detectable levels of phosphorylated c-Jun was observed in static or vasoprotec-
tive shear stress, but pro-remodeling cultures had increased slight increase in nuclear
localization of phosphorylated c-Jun. Stimulation with TNFα increased nuclear lo-
calization across all shear conditions. (B) Alternatively, cells were fixed with 4%
PFA, and lysed with a 1% SDS lysis buffer to recover chromatin-protein complexes.
Genomic DNA was sheared and isolated based on manufacturer’s instructions. TNFα
increased phosphorylated c-Jun binding to the cathepsin K promoter region by 2.7-
fold under static and by 28-fold under vasoprotective shear conditions. (C-D) Ad-
ditionally mRNA was isolated and cathepsin K gene expression was quantified with
qRT-PCR. n=3, * denotes statistical significance with p<0.05.
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5.3.3 Shear Stress Regulates Cathepsin K Gene Expression via NFκB
Signal Transduction
To elucidate the multi-pathway cross talk in the synergistic regulation of proteolysis
by biomechanical and inflammatory stimuli, we next investigated the roles of alter-
native downstream kinase pathways. Intracellular responses to TNFα-stimulation in
endothelial cells are often divided into two canonical pathways: (1) JNK activation
and downstream signaling, and (2) nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NFκB) translocation and transcriptional regulation. There is evidence
to suggest that regulation and activation of NFκB is shear stress regulated, and has
been implicated in arterial remodeling in vivo [135, 43, 102]. Therefore, we next in-
vestigated the potential for NFκB to function as the shear stress responsive element
in endothelial cell cathepsin K activation. Immunostaining for total NFκB expres-
sion indicated that vasoprotective shear stress significantly decreased whole-cell levels
of NFκB compared to pro-remodeling shear stress, regardless of TNFα stimulation
(Fig 5-7). The decreased bioavailability of NFκB in response to vasoprotective shear
stress was confirmed via Western blot (Fig 5-7).
To directly establish a link between NFκB and cathepsin K, we next tested the
hypothesis that preventing the activation of NFκB would inhibit pro-remodeling ac-
tivation of cathepsin K. Inhibition of NFκB activation reduced cathepsin K activity
under pro-remodeling shear stress, both with and without TNFα, to undetectable lev-
els (Fig 5-8 Lanes 7 and 8). Interestingly, inhibition of NFκB activation significantly
reduced cathepsin K activity in pro-remodeling cultures by 0.5-fold (Fig 5-8 Lane 7
vs Lane 3), and pro-remodeling cultures co-stimulated with TNFα were reduced by
0.9-fold (Fig 5-8 Lane 8 vs Lane 4); inhibition of NFκB activation had no signifi-
cant effect on TNFα-mediated induction of cathepsin K activity. Additionally, there
was no significant change in total NFκB protein levels due to inhibition of NFκB
activity. The findings from this data implicate shear-regulated NFκB signaling in
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Figure 5-7: TNFα and vasoprotective shear stress decrease NFκB protein
levels. Cultures were either lysed for Western blot analysis, or fixed with 4% PFA for
immunohistochemistry, and stained for NFκB (green); cultures were counterstained
with phalloidin (red) for actin, and Hoechst (blue) for nuclei. (A) Western blot
analysis of culture lysates show a decrease in detectable, whole-cell NFκB protein
levels in vasoprotective culture. (B) Pro-remodeling cultures had detectable levels of
phosphorylated NFκB, but (C&E) vasoprotective cultures had substantially decreased
NFκB expression.
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pro-remodeling-induction of cathepsin K activity.
5.4 Discussion
In this study, we investigated how large artery endothelial cells integrate biochem-
ical and biomechanical signals; specifically intracellular kinase signal pathway by
which physiological shear stress mitigated or enhanced TNFα-stimulated cathepsin
K, a powerful elastase and collagenase upregulated in other cardiovascular disease
[111, 110, 80, 81]. We show here that active cathepsin K is increased in response
to pro-remodeling shear stress, a physiological shear stress waveform known to in-
duce arterial wall remodeling and atherosclerotic plaques. Additionally, cultures co-
stimulated with pro-remodeling shear stress and TNFα, which we have shown previ-
ously to activate cathepsin K in endothelial cells [68, 67], increased average cathepsin
K activity in endothelial cells, although the increase was not significant (Fig 5-5).
Conversely, vasoprotective shear stress significantly reduced TNFα-stimulated induc-
tion of cathepsin K (Fig 5-2) independent of the JNK/c-Jun signaling pathway (Fig 5-
5). These data suggest that cathepsin K activation in large artery endothelial cells is
regulated by distinct signaling pathways that respond independently to biochemical
(TNFα) or biomechanical (shear stress). Examination of cathepsin K gene expression
indicated that TNFα induced nuclear localization of phosphorylated c-Jun and subse-
quent binding to the cathepsin K promoter region, regardless of shear stress conditions
(Fig 5-6 A-B); however, vasoprotective shear stress did significantly decrease overall
cathepsin K gene expression (Fig 5-6 C-D). Furthermore, we demonstrated that va-
soprotective shear stress reduces NFκB protein levels in HAECs maintained under
vasoprotective shear stress, compared to cultures maintained under pro-remodeling
shear stress (Fig 5-7), and inhibition of NFκB activity significantly reduced activation
of cathepsin K by pro-remodeling shear stress (Fig 5-9). Based on the findings of this
study, the loss of cathepsin K activity and expression in response to TNFα in cultures
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Figure 5-8: Shear stress-mediated activation of cathepsin K is dependent
on NFκB activation. Confluent HAECs were pre-conditioned with 5µM of Bay 11-
7082, an inhibitor of NFκB activation, for 1 hour prior to being stimulated with or
without 10ng/mL TNFα, and maintained in static (lanes 1, 2, 5, 6), or pro-remodeling
(lanes 3, 4, 7, 8) shear stress for 20 hours. Cultures were lysed and (A) cathepsin
activity was determined using multiplex cathepsin zymography, and NFκB protein
levels were determined using Western blot, and (B) quantified using densitometry
analysis. Pro-remodeling shear stress alone induced detectable levels of cathepsin
K activity, but inhibition IκBα phosphorylation prevented detectable cathepsin K
activity.
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Figure 5-9: Schematic representation of biomechanical and biochemical reg-
ulation of cathepsin K activity in endothelial cells. Proposed mechanism by
which vasoprotective shear stress inhibits cathepsin K protein expression and activa-
tion downstream of TNFα stimulation via reduced NFκB activation and expression.
maintained under vasoprotective shear stress suggests that transcriptional activation
cathepsin K gene may be dependent on the ability for both c-Jun and NFκB to bind
to the promoter region.
Vascular biomechanical studies have established that regions of the vasculature
exposed to vasoprotective shear stress are protected from vascular remodeling, while
regions exposed to pro-remodeling shear stress are more vulnerable [59, 80, 88, 152,
49, 32]. Work done by our group has previously correlated increased active cathepsin
K levels at sites of disturbed flow to arterial remodeling [111, 110]. Additionally, the
initiation of arterial remodeling pathologies is the result of endothelial cell dysfunction
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and activation from inflammatory cytokines, such as TNFα [151, 71]. The findings
from this study provide a mechanistic link for how arterial endothelial cells integrate
biomechanical shear stress and inflammation to differentially regulate cathepsin K,
which has particular relevance for those suffering from sickle cell disease. People
with sickle cell disease suffer from a chronic inflammatory syndrome characterized
by elevated TNFα and chronic activation of vascular endothelial cells, which may
induce upregulation of cathepsin K throughout the vasculature. Additionally, tran-
sient aggregation of red and white blood cells along the arterial wall may generate
spontaneous regions of pro-remodeling shear stress [11], allowing regions of the vascu-
lature to become vulnerable to cathepsin-mediated arterial remodeling. The findings
from this study implicate that c-Jun phosphorylation and NFκB are necessary for
up-regulation of cathepsin K. Work done by others have found NFκB activity to be
increased in regions of pro-remodeling shear stress in mice, and in vivo inhibition of
NFκB protects against atherosclerotic lesion formation [43, 51]. Furthermore, TNFα
stimulation of HAECs stimulates NFκB to complex with phosphorylated c-Jun and
bind to the TPA response element in human aortic endothelial cells [117, 126], which
is present in the cathepsin K promoter region. Therefore, we conclude that TNFα is
sufficient to induce cathepsin K activity only if there is sufficient NFκB availability to
allow for activation of the TPA response element on the cathepsin K promoter region;
loss of NFκB signaling or expression, as is seen after exposure to vasoprotective shear
stress or through inhibition with Bay 11-7082, significantly cathepsin K expression
and activity.
The identification of NFκB as a shear-responsive activator of cathepsin K ex-
pression provides a novel therapeutic target for for people suffering from sickle cell
disease, especially children who have a 220-fold increase in the chance of stroke be-
fore the age of 20 as a resulting from advanced arterial remodeling of the middle
cerebral and carotid arteries [133, 3, 4, 2, 116]. Based on previous work establishing
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cathepsin-mediated arterial remodeling and elastin degradation in other vascular dis-
eases, such as atherosclerosis, in conjunction with our findings that TNFα increases
active cathepsin K activity in large artery endothelial cells [68], we hypothesize that
pathological activation of cathepsin K may also contribute to rapid cerebral arterial
remodeling leading to stroke [67]. Due to the effects of elevated plasma levels of
TNFα and it potential to induce cathepsin K expression and activity, combined with
the altered rheology of sickle red blood cells and the possibility of spontaneous gen-
eration of pro-remodeling shear stress anywhere along the arterial tree, we posit that
people with sickle cell disease are uniquely vulnerable to sustained, upregulation of
cathepsin K within the arterial wall leading to rapid arterial remodeling. Although
regular blood transfusions have been shown to mitigate the risk of stroke in young
children with sickle cell disease, the chronic transfusions needed carry significant and
life-threatening risks of alloimmunity, iron over load, and infection; however, this re-
mains the only available therapy as there are currently no pharmaceutical treatment
options available. By identifying other mechanistic pathways by which cathepsin ac-
tivity is regulated by the hemodynamic and inflammatory environment of sickle cell
disease, these may present new therapeutic targets for reduction in the risk of death
for young children with sickle cell disease.
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CHAPTER VI
SYSTEMIC INHIBITION OF JNK PREVENTS
CATHEPSIN K MEDIATED VASCULOPATHY IN
CAROTID ARTERIES OF SICKLE TRANSGENIC MICE
6.1 Introduction
Sickle cell disease is a genetic disorder affecting nearly 100,000 Americans and millions
worldwide. Although commonly regarded as a hematological disorder characterized
by the unique, ”sickle” red blood cells, people with sickle cell disease have an 11%
chance of a major stroke before the age of 20, and a 35% chance of a silent stroke
before the age of 16; children are at the highest risk between 2 and 5 years old
[10, 2, 115]. Post-mortem examination of the cerebral vasculature of children who have
suffered strokes revealed significant luminal narrowing, as well as delamination and
fragmentation of the internal elastic lamina of the internal carotid and middle cerebral
arteries [133, 53, 116]. Moreover, in contrast to other cardiovascular diseases in which
vascular remodeling develops over decades prior to clinical presentation, sickle cell
disease induces arterial remodeling at a dramatically accelerated rate. Despite the
high risk and rapid formation of arterial remodeling in sickle cell disease, there is
little consensus on how these vascular lesions are initiated or progress. However, the
rapid and extensive remodeling of the carotid and cerebral arteries of young children
with sickle cell disease led our group to hypothesize that pathological proteolytic
remodeling may play an important role in vascular lesion development.
Research on the development of pathological arterial remodeling have indicated
that specific, predictable regions of the vascular tree are vulnerable, specifically sec-
tions that are characterized by sharp bends or bifurcations, such as the carotid and
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cerebral arteries, due to the generation of low, oscillatory shear stress [152, 73, 49, 32].
Additionally, work done by our group and others has elucidated that one of the key
effects of sustained oscillatory blood flow is the activation and secretion of powerful
proteases into the arterial wall, leading to degradation of the elastic lamina, a prin-
ciple initiating step of further pathological remodeling. As mentioned previously, we
are interested cathepsin K’s involvement in arterial remodeling in sickle cell disease
due to it being a potent elastase and its established role in other cardiovascular dis-
eases. In addition to regions of sickle-mediated arterial remodeling, namely the carotid
and cerebral arteries, being identified as inherently vulnerable to increased cathep-
sin activity, our work has identified that the often overlooked chronic inflammatory
syndrome generated by sickle cell disease also generates a perpetual pro-cathepsin
environment within the vasculature. People with sickle cell disease have chronically
elevated inflammatory cytokines, such as tumor necrosis alpha (TNFα), which is suf-
ficient to induce cathepsin K in arterial endothelial cells via JNK and c-Jun signaling
[68]. Additionally, people with sickle cell disease have higher numbers of circulating
monocytes in the peripheral blood, and these monocytes are also uniquely conditioned
to also be able to induce cathepsin K activity in endothelial cells, again dependent on
JNK and c-Jun signaling [67]. Therefore, it is apparent that the chronic inflamma-
tion characteristic to sickle cell disease, in conjunction with the natural geometry and
hemodynamics of the carotid and cerebral arteries generate a powerful pro-cathepsin
environment for the development and progression of arterial remodeling.
Developed in the late 1990s, the Townes transgenic murine model successfully
recapitulates many of the symptoms and comorbidities seen in humans [16]. Mice
were genetically modified such that the murine hemoglobin genes were knocked out
and human hemoglobin genes, including those that contain the sickle mutation, were
knocked in. However, there remains a need for more comprehensive characterization
of the vascular and neural pathologies associated with sickle cell disease in the Townes
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model. Furthermore, a more complete characterization of the animal model would be
benefit the continued investigation and development of pharmacological therapeutics
for the prevention and treatment of stroke in sickle cell disease. Therefore, the purpose
of this study was three-fold. First, we tested the hypothesis that sickle transgenic mice
develop vasculopathies analogous to what is observed clinically in the cerebral and
carotid arteries leading to stroke in the Townes model of sickle cell disease. Second, we
tested the hypothesis that vascular remodeling in vivo was the result of pathologically
elevated cathepsin K activity within the arterial wall. Third, we hypothesized that
inhibition of JNK signaling in vivo, based on our previous findings in vitro, would
be sufficient to reduce cathepsin K expression and activity, thereby preventing the
initiation and progression of arterial remodeling in sickle cell disease.
6.2 Methods
6.2.1 Animals
Townes sickle transgenic mice (B6; 129-Hbatm1(HBA) Tow Hbbtm2 (HBG1,HBB*)
Tow/Hbbtm3 (HBG1,HBB) Tow/J) were obtained from Jackson Laboratories and
used to establish a breeding colony in the Physiology Research Laboratory at Georgia
Tech. Animals were housed according to a 12:12 light:dark cycle and fed an ad lib
diet. Pups born to breeders were sexed and separated into different cages at 21
days old. All mice were housed and all experiments were conducted with approval of
the Georgia Institute of Technology Institutional Animal Care and Use Committee
(protocol number A13011) and the supervision of the Physiology Research Laboratory
veterinarian technologists.
6.2.2 Identification of Normal and Sickle Hemoglobin
Animals were evaluated for entry into the drug trial based on sickle status at 21 days
old. Animals were anesthetized using an 3% isoflurane and approximately 600µL
of whole blood was obtained via retro orbital blood draw into heparinized blood
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Figure 6-1: Identification of sickle status of transgenic mice using Native
PAGE. Whole blood samples were obtained via retro-orbital blood collection and
lysed with 1mL of distilled water. Hemoglobin was run using standard Native PAGE
to isolate normal hemoglobin at a smaller hydrodynamic radius, resulting in faster
migration and development of a lower band. Sickle hemoglobin has a larger hemo-
dynamic radius, resulting in slower migration and development of a higher band.
Representative image is shown.
collection tubes. Whole blood was lysed with 500µL 100% dH2O and spun at 90,000xg
for 10 minutes to pellet cellular debris leaving hemoglobin within the supernatant.
The hemoglobin was then categorized based on the electrophoretic migration distance
through a standard Native PAGE protocol. Briefly, the supernatant was diluted 1:8 in
a 50% glycerol solution and 20µL was loaded into a modified 12.5% polyacrylamide
gel lacking SDS. The gel was run for 2 hours at 100V using a 3% Tris base and
14.18% glycine running buffer. Gels were imaged using an ImageQuant 4010 system
(GE Healthcare). Since hemoglobin containing the sickle mutation has a slightly more
positive electrical charge, compared to normal hemoglobin, sickle hemoglobin will not
migrate as far through a Native PAGE gel. Therefore, animals with a single, high
hemoglobin band were classified as homozygous for sickle cell disease (SS), animals
with a doublet band were classified as sickle trait (AS), and animals with a single,
low hemoglobin band were classified as normal (AA, Fig 6-1).
6.2.3 JNK Inhibition
For the JNK inhibition drug trial, 9 animals were selected at 21 days old and sickle
status was determined; a total of 2 AA animals, 4 AS animals, and 2 SS animals
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were enrolled. Animal weights were determined at the onset and weekly measure-
ments were taken for the duration of the drug study. The inhibitor of JNK activity,
SP600125 (Invitrogen), was diluted in 10% DMSO and injected intraperitoneally at
a concentration of 50mg/kg of animal body weight. Injections were performed daily
over the course of 8 weeks, and animal weights were monitored according to IACUC
policy as an indicator of general animal health.
6.2.4 Tissue Isolation
Animals were euthanized after 8 weeks using CO2 asphyxiation. After termination,
the animal’s thoracic cavity was exposed and a 28 gauge catheter was inserted 2-
4mm through the apex of the heart and into the left ventricle. The ascending vena
cava was cut and the circulatory system of the animal was perfused with via gravity-
driven system with physiological saline for 5 minutes to remove residual blood. The
spleen, along with the thoracic aorta, heart, left and right common carotid arteries,
and brain was then isolated. Relative size and weight of the heart and spleen were
measured and recorded. The thoracic aorta was cleaned of surrounding adventitia,
and placed in 60µL of zymography lysis bufferLi:2010km, Wilder:2011gk with 0.1mM
leupeptin. Additionally, the carotid arteries were carefully cleaned of adventitia and
placed in 10% neutral buffered formalin for 30 minutes, and then embedded in His-
toGel (Richard-Allen Scientific). Brains were removed via craniotomy and placed in
10% neutral buffered formalin for 24 hours.
6.2.5 MRI scans of sickle transgenic mice brains
After fixation, brains were immersed and embedded in a 2% agarose (Phenix Research
Products) with 2mM Gadolinium(III) oxide (Acros Organics) overnight. The brains
were then scanned using a Bruker 9.4 Tesla magnet with a T2-weighted protocol (TE
= 13.4 ms. TR= 10,000, 512 x 512 x 70).
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6.2.6 Arterial Elastin Morphology
HistoGel-embedded carotid arteries and isolated brains, not selected for MRI imaging,
were imbedded were paraffin processed and 5µm sections were obtained and select
serial sections were deparaffinized. Elastin was visualized using a modified Verhoeff
elastic-van Gieson stain (Electron Microscopy Sciences). Briefly, sections were placed
in a modified Verhoeff elastic solution (3 parts 3% Hematoxylin, 2 parts 2% ferric
chloride, 1 part Lugol’s idodine) for 7 minutes, and washed with warm water for
1 minute. Samples were then resolved in 0.4% ferric chloride for 75 seconds, rinsed
again with warm water for 5 minutes, and counter-stained with Van Gieson’s solution
for 60 seconds. Slides were then dehydrated, cover-slipped, and imaged with a Ti-
Eclipse microscope (Nikon Instruments). For elastin fragmentation quantification,
carotid artery sections were blinded and imaged under 40x magnification, and areas
of elastin fraying, fragmentation, and delamination were identified and recorded by
eye (n3, p¡0.05).
6.2.7 Immunohistochemistry for Cathepsin K
Deparaffinized sections of carotid arteries or brain tissue were permeabilized with
0.2% Triton X for 15 minutes, washed 3x with PBS, followed by antigen retrieval
using 0.1% trypsin for 15 minutes at room temperature. Samples were washed again
3x with PBS and blocked with 2% BSA for 1 hour at room temperature. Slides were
stained with a 1:50 dilution of rabbit monoclonal anti-mouse cathepsin K (Santa
Cruz Biotechnology) for 24 hours at 4C, washed in PBS, and stained again with
AlexaFluorTM 488 secondary antibody (Invitrogen). Slides were counter stained with
a 1:20 dilution of AlexaFluorTM 562 phallotoxin (Invitrogen) for 10 minutes to visual-
ize actin filaments. Slides were washed a final time in PBS and mounted with Prolong
Gold anti-fade mounting media containing DAPI (Invitrogen) for visualization of the
nucleus.
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6.2.8 Fluoro Jade B Staining of Degenerating Neurons
Select animals were fixed through perfusion of 10% neutral buffered formalin through
the left ventricle of the heart using a gravity-fed perfusion system; brains were iso-
lated and processed for paraffin embedding, 5µm sections were obtained and samples
were dried for 30 min at 50C. Sections were postfixed with 4% neutral buffered for-
malin again, and washed 3x with PBS. Slides were incubated in 0.06% potassium
permanganate for 10 minutes on a table shaker, and washed twice with distilled wa-
ter, followed by incubation in 0.0004% Fluoro Jade B (Milipore) solution containing
0.1% acetic and 0.0004% DAPI solution for 20 minutes at room temperature. Slides
were rinsed 3x for 2 minutes, and placed in an over at 50C until fully dried. Fi-
nally, slides were cleared by immersion in xylene for 2 min before cover slipping with
Prolong Gold mounting medium (Invitrogen).
6.2.9 Multiplex Cathepsin Zymography
Multiplex cathepsin zymography was used to assess cathepsin activity in the arterial
walls of mouse thoracic aortas. Excised suprarenal were placed in 50µL of lysis buffer
(20 nM Tris-HCl [pH 7.5], 5mM ethylene glycol tetraacetic acid [EGTA], 150mM
NaCl, 20mM β-glycerol phosphate, 10mM NaF, 1mM sodium orthovanadate, 1%
Triton X-100, and 0.1% Tween 20) with 0.1mM leupeptin, homogenized using dis-
posable sample grinders (GE Healthcare). Additionally, whole brain lysates were ob-
tained through use of a neural tissue dissociation kit (Miltenyi Biotec). Briefly, whole
brains were minced in ice cold PBS and enzymatically dissociated at 37 degrees C
for 15-20 minutes. The solution was then passed through a 40 µm cell strainer to
render a single cell suspension. Cells were pelleted at 500xg for 10 minutes, and lysed
with 60µL of lysis buffer with 0.1mM leupeptin added fresh. Protein concentrations
were obtained by the bicinchoninic acid (BCA) assay (Pierce). Cathepsin zymogra-
phy was performed as described previouslyLi:2010km, Wilder:2011gk, Hansen:2012ef,
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Hansen:2013gc. Gels were imaged using an ImageQuant LAS 4000 (GE Healthcare).
6.2.10 Statistical Analysis
Each experimental condition was repeated with a minimum of three biological repli-
cates, and each data point is presented as the mean value and standard error of the
mean. Representative images are shown.
6.3 Results
6.3.1 Sickle Cell Disease Promotes Cathepsin Mediated Elastin Degra-
dation of the Carotid Arteries
After identification of each animal as normal, trait, or sickle transgenic, animals
were inspected for hallmark pathologies associated with sickle transgenic animals.
Spleens from euthanized animals were excised and measured. Normal (AA) and trait
(AS) spleens were of comparable size, but sickle spleens were substantially larger,
consistent with both human pathophysiology (Fig 6-2, representative image shown).
Additionally, hearts from each animal were also isolated and measured for relative
size differences. Again, there was no substantive difference between normal and sickle
trait animals, but sickle transgenic animals had larger hearts, specifically with regards
to the left ventricle Fig 6-3, suggesting that sickle transgenic mice have increased
peripheral resistance caused by vasooclusion.
We first investigated if sickle cell disease in transgenic animals induced vascular
remodeling similar to what has been clinically observed in humans. 5µm sections
of the common carotid arteries isolated animals after gravity perfusion fixation with
10% neutral buffered formalin (NBF), prepared for paraffin histology. Elastin mor-
phology was visualized through modified Verhoeff elastic-van Gieson stain. Sickle
transgenic (SS) mice had 8-times more elastin fragmentation compared to sickle trait
(AS) animals (Fig 6-4, orange arrowheads); however, there was no significant differ-
ence between AS animals and normal (AA) animals (data not shown).
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Figure 6-2: Comparison of spleen sizes isolated from normal and trasngenic
sickle mice. Normal (AA), trait (AS), and sickle transgenic (SS) mice were eutha-
nized and the spleens were isolated and measured along their longest axis. Spleens
from normal and sickle mice were of comparable length, and spleens from sickle ani-
mals were substantially larger; representative images shown.
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Figure 6-3: Sickle cell disease increases size of left ventricle in transgenic
mice. Hearts were isolated from normal (AA), trait (AS), and sickle transgenic (SS)
mice and measured to determine relative size differences. Normal and trait animals
had comparable heart sizes, but sickle transgenic animals were markedly larger.
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Figure 6-4: Sickle cell disease promotes elastin fragmentation in transgenic
mice. Perfusion fixed carotid arteries from trait and transgenic mice were isolated,
sectioned, and stained for elastin morphology using modified Verhoeff elastic-van
Gieson stain. (A-C) Sickle transgenic mice had significantly smaller luminal areas,
and (D) significantly increased incidence of elastin fragmentation, compared to trait
mice. * denotes p<0.05, n=4.
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Furthermore, carotid arteries in sickle transgenic mice had more linear elastin
fibers compared to trait animals, indicated by a higher form factor, which suggests
carotid arteries in these animals may have significantly altered biomechanical prop-
erties. Loss of elastin integrity also resulted in a significant increase in luminal area
in SS mice, compared to AS mice, further implicating onset of pathological arterial
remodeling (Fig 6-5; p<0.05, n=4.)
Work done previously by our group, and others, has implicated cathepsin K in
cardiovascular remodeling pathologies, such as atherosclerosis. Furthermore, we have
also shown that the circulatory environment in sickle cell disease is sufficient to induce
elevated cathepsin K activity in arterial endothelial cells [67]. Therefore, we next
investigated if areas of elastin fragmentation coincided with elevated cathepsin K
expression. Serial sections of AA, AS, and SS carotid arteries were obtained and
immunostained for cathepsin K protein levels. SS mice had substantially higher
cathepsin K protein expression within the arterial, compared to both AA and AS
animals (Fig 6-6). Furthermore, the elevated cathepsin K activity co-localized to
regions of elastin fragmentation. These data suggest that sickle cell disease promotes
elastin degradation and arterial remodeling through up-regulation of cathepsin K
protein expression within the arterial wall. Next, we investigated the repercussion of
sickle cell disease on the vessel integrity of the cerebral arteries.
6.3.2 Sickle transgenic mice develop cerebral vasculopathy and stroke
In addition to the carotid arteries, clinicians have identified that strokes associated
with sickle cell disease occur as a result of remodeling and occlusion of the cerebral
arteries. Sickle trait and sickle transgenic mice were euthanized and perfusion fixed
using 4% PFA, followed by craniotomy to remove the brain. 5µm section were ob-
tained and histologically stained with a modified Verhoeff elastic-van Gieson stain
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Figure 6-5: Sickle cell disease promotes arterial remodeling leading to in-
creased luminal area of carotid arteries. Perfusion fixed carotid arteries from
AS and SS mice were isolated, sectioned, and stained for elastin morphology using
modified Verhoeff elastic-van Gieson stain. Images were analyzed using photomasking
and image analysis to quantify luminal area, eccentricity, form factor, and perimeter.
* denotes p<0.05, n=4.
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Figure 6-6: Sickle cell disease upregulates cathepsin K in transgenic mice.
Perfusion fixed carotid arteries from trait and transgenic mice were isolated, sectioned,
and immunostained for the presence of cathepsin K protein. Only sickle transgenic
animals possessed positive cathepsin K staining (orange) in the arterial wall, with
undetectable levels in normal and trait animals; elastin fibers are autofluorescent
(green).
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Figure 6-7: Sickle transgenic mice develop luminal narrowing and elastin
remodeling in middle cerebral artery. Histological sections of whole brains
were obtained and stained for elastin morphology using modified Verhoeff elastic-van
Gieson stain, and the middle cerebral artery was imaged. Sickle transgenic animals
present advanced elastin remodeling (orange arrowheads), as well as aggregations of
blood cells along the vessel wall (white arrowheads); trait animals did not present
any detectable elastin remodeling or cell aggregations.
to visualize elastin structures. Sickle transgenic animals presented regions of sig-
nificant remodeling within the middle cerebral artery characterized by pathological
elastic reorganization (orange arrowheads), luminal narrowing, and aggregations of
red blood cells along the arterial wall (white arrowheads); AS animals had no dis-
cernible remodeling, elastin fragmentation, or accumulation of circulating red blood
cells (Fig 6-7). These data suggest that sickle cell disease uniquely induces cerebral
arterial remodeling, as well as promotes aggregations of circulating blood cells along
the luminal wall, potentially leading to arterial dysfunction and obstruction of blood
flow.
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Figure 6-8: Brains from sickle transgenic mice have elevated cathepsin ac-
tivity. Whole brains were isolated from 12-24 week old trait and transgenic mice,
enzymatically dissociated, lysed, and cathepsin activity was assayed using multiplex
cathepsin zymography. Brains from sickle transgenic mice have markedly increased
cathepsin activity, compared to trait animals; cathepsin activity also appears to in-
crease with age.
Additionally, brains from 24-week-old AS mice, as well as 12- and 24-week-old
SS mice were isolated without perfusion fixation. Wholes brains were enzymatically
disassociated, and the resulting single cell suspension was collected and lysed for zy-
mography. Interestingly, SS mice had substantially higher levels of active cathepsins,
which increased with age; ASS animals had no detectable cathepsin K activity (Fig 6-
8). These results suggest that, like the carotid arteries, sickle cell disease also induces
in vivo arterial remodeling of the cerebral arteries, potentially through pathologically
elevated cathepsin K activity.
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Figure 6-9: Sickle cell disease generates potential stroke lesions and in-
crease neuronal death in transgenic animals. Isolated brains from sickle trait
or transgenic animals were imbedded in gadolinium (III) oxide-agarose gel and imaged
using a 9.4T animal MRI scanner running a T2-weighted modality. (A-B) Transgenic
mice develop dark regions (red arrows) that are indicative of cerebral damage due to
stroke. (C-D) Additionally, histological sections of whole mice brains were stained
with FluroJadeB to identify perimortem neuronal cell death (bright green). Sickle
transgenic animals had higher incidence of positive FluorJadeB staining, compared
to trait animals.
Based on the our findings of arterial remodeling evidenced by increased luminal
area, form factor, and incidence of elastin fragmentation in the carotid arteries of SS
mice, we also tested the hypothesis that transgenic animals developed stroke lesions
akin to what is observed in humans. AS and SS mice were euthanized and perfu-
sion fixed, as previously discussed, and the brains were isolated and imbedded in a
gadolinium (III) oxide-agarose gel. The brains were subsequently imaged using with
a 9.4-Tesla MRI scanner running a T2-weighted imaging modality. Examination of
the scans indicated both the sickle transgenic mice develop brain lesions indicative of
stroke (Fig 6-9, red arrows), while sickle trait animals do not develop any lesions.
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6.3.3 In vivo inhibition of JNK signaling reduces arterial cathepsin K
expression and activity in sickle transgenic animals
Work done previously by our group has effectively established that the pro-inflammatory
circulatory environment of sickle cell disease is sufficient to induce cathepsin K activ-
ity in large artery endothelial cells via JNK/c-Jun signaling [67, 68]. Additionally, the
findings in this study have established a strong correlation between increased cathep-
sin K activity and expression in the carotid and cerebral arteries of sickle transgenic
animals, exclusively. Therefore, we next determined if in vivo inhibition of JNK sig-
naling would inhibit arterial cathepsin K and prevent elastin degradation, preserve
arterial structure, and prevent stroke lesion formation. Nine mice were divided into
drug treatment and vehicle groups based on genotype (Fig 6-10), and were given IP
injections of 50mg/kg of the JNK inhibitor SP600125 daily for 8 weeks.
After, animals were euthanized and the thoracic aorta and common carotid arter-
ies were isolated after perfusion fixation. Over the course of the 8 weeks, the systemic
injections of SP600125 had no significant effect on the animals overall health, be-
havior, or weight. Tissue lysates were collected from the thoracic aortas and system
inhibition of JNK activity was quantified by immunoblotting for c-Jun phosphoryla-
tion. The SS animal and AS animals had increased baseline levels of phosphorylated
c-Jun, compared to the normal animals (Fig 6-11). Additionally, all mice injected
with SP600125, regardless of sickle status, exhibited substantial reduction in c-Jun
phosphorylation after 8 weeks of injection, compared to the vehicle control group
(Fig 6-11) indicating that daily injections of the inhibitor SP600125 were sufficient
to reduce physiological levels of JNK activity in arteries.
Having established that the JNK inhibitor successfully reduced JNK/c-Jun sig-
naling within arteries of the mice, we next investigated if the effect of sustained JNK
inhibition on the development of sickle cell disease related vasculopathy. 5/mum his-
tological sections of the common carotid artery were obtained and serial sections were
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Figure 6-10: Sickle status, age, and bodyweight of animals receiving daily
injections of SP600125. Littermate mice were blood typed to determine sickle
status, and placed into the drug treatment or placebo groups. Animal ages and
weights were recorded at initiation and termination of the study as indicators of
general animals health. There was no substantial difference in animal weights in the
drug versus placebo group.
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Figure 6-11: Intraperitoneal injections of SP600125 reduces arterial c-Jun
phosphorylation. Thoracic aortas were isolated from drug and placebo group an-
imals, and whole tissue lysates were assessed for c-Jun phosphorylation via Western
blot. Sickle trait and transgenic animals had elevated phosphorylated c-Jun compared
to normal animals, but all participants had marked decrease in c-Jun phosphorylation
after injections of SP600125.
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stained for elastin morphology and cathepsin K protein expression. As expected, the
SS mice had 11 times more instances of elastin fragmentation within the wall of the
carotid artery, compared to AA and AS mice (Fi 6-12). Furthermore, the total lumi-
nal area of carotid arteries from sickle mice were XX-times greater, compared to both
normal and trait animals, indicating increased degradation of the elastin fibers within
the arterial wall leading to decreased circumferential strain (Fig ). Interestingly, how-
ever, inhibition of JNK signaling reduced both the instances of elastin fragmentation
and luminal area of sickle transgenic animals to levels comparable to both treated and
untreated AA and AS animals, suggesting that inhibition of the JNK/c-Jun signaling
axis may be sufficient to prevent the development of sickle cell disease induced elastin
degradation.
Based on our previous findings that cathepsin K activation is downstream of
JNK/c-Jun signaling in vitro, and that cathepsin K protein co-localized with areas
of elastin fragmentation in sickle transgenic mice, we next investigated the effect of
in vivo inhibition of JNK signaling on cathepsin K protein expression in the carotid
arteries of transgenic mice. Immunostianing for cathepsin K protein indicated a sub-
stantially higher level of protein expression throughout the arterial wall in SS animals,
with little to no staining apparent in AS or AA animals. However, administration
of the JNK inhibitor substantially reduced protein staining in the sickle transgenic
animal, indicating that inhibition of JNK signaling inhibits sickle cell disease-induced
cathepsin K expression in the arterial wall (Fig 6-13). Additionally, we assayed overall
cathepsin activity in the mice using multiplex cathepsin zymography on tissue lysates
obtained from the thoracic aortas. As expected, sickle transgenic mice had elevated
total cathepsin activity, compared to normal and trait mice; however, inhibition of
JNK signaling reduced cathepsin activity in transgenic, paralleling what was observed
in the carotid arteries and previous in vitro studies (Figure 6-14). Taken together,
we have established in this study that sickle cell disease results in over expression of
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Figure 6-12: Inhibition of JNK signaling reduces elastin fragmentation in
carotid arteries of transgenic mice. Carotid aortas were isolated from drug and
placebo group animals, sectioned, and histologically stained for elastin morphology.
Sickle transgenic animals receiving daily injections of the JNK-inhibitor SP600125
had substantially reduced incidence of elastin fragmentation compared to both trait
and normal animals.
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Figure 6-13: Inhibition of JNK signaling inhibits cathespin K protein ex-
pression in carotid arteries of transgenic mice. Carotid aortas were isolated
from drug and placebo group animals, sectioned, and immunostained for cathepsin
K protein. Sickle transgenic animals receiving daily injections of the JNK-inhibitor
SP600125 had substantially weaker staining for cathepsin K, compared to the placebo
group.
cathepsin K within the wall of the carotid artery, leading increased elastin fragmen-
tation; however, systemic inhibition of JNK signaling is sufficient to reduce cathepsin
K protein expression and activity, ultimately leading to better arterial integrity.
6.4 Discussion
In this study we are the first group to identify systematically characterize the devel-
opment of vascular remodeling in the gold standard Townes sickle transgenic mouse
model. Sickle transgenic mice present increased elastin fragmentation and remodel-
ing in the carotid artery, evidenced by increased numbers of elastin breaks within
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Figure 6-14: Inhibition of JNK signaling reduces arterial cathepsin activity
in sickle transgenic mice. Whole tissue lysates were collected from the thoracic
aortas of normal, trait, and transgenic mice and cathepsin activity was assayed us-
ing multiplex cathepsin zymography. Sickle transgenic animals had higher baseline
cathepsin activity, but administration of the JNK inhibitor SP600125 substantially
reduced activity.
the arterial wall (Fig 6-4). Furthermore, the luminal area of the carotid arteries
of sickle mice was significantly larger than normal and trait mice, which is indica-
tive of elastin degradation and loss of circumferential stress (Fig 6-5). Additionally,
we determined that sickle transgenic mice have increased elastin fragmentation and
pathological elastin restructuring within the middle cerebral artery (Fig 6-7), in-
dicating that the Townes model of sickle cell disease recapitulates two important
hallmarks of vascular degeneration found in human patients. Additionally, we not
only identified that sickle cell disease induces substantially higher cathepsin K ex-
pression, that co-localizes with elastin degradation, in both the carotid and cerebral
arteries, compared to both trait and normal mice, but that animals with sickle cell
disease have higher cathepsin activity in their brain (Fig 6-7 and 6-6). Our group
is also the first to identify increased neural death and the potential development of
stroke lesions in sickle transgenic animals (Fig 6-9). In addition to being the first to
describe and characterize the vascular pathology of sickle transgenic mice, our group
was also able to use systemic inhibition of JNK signaling to reduce not only cathepsin
K expression and activity in the carotid arteries of sickle mice, but also decrease the
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elastin degradation observed in untreated animals.
Numerous investigations of sickle cell disease have focused on the generation of
the vasoocclusive crises that forms due to aggregations of sickled red blood cells
obstructing blood flow through the microvasculature, resulting in damage to bone [5],
spleen [105], lungs [84], and many other organ systems, while simultaneously inducing
extreme pain that can last anywhere from hours to days. In the past decade, research
stemming from vasoocclusive crises has begun to examine the role of the abnormally
adherent, stiff, oxidizing sickle red cells as an irritant that provokes an inflammatory
response as it obstructs flow [114]. In vivo investigations using the Townes transgenic
mouse model have implicated reperfusion injury as a possible source for the chronic
inflammatory syndrome of sickle cell disease that is also observed in human subjects
[63]. Ischemia followed by reoxygenation of the vasculature in sickle mice generated
a distinct inflammatory response with increased rolling, adhesion, and emigration
of vascular white blood cells facilitated by endothelial surface expression of adhesion
molecules, implying that reperfusion following vasoocclusive crises in sickle cell disease
results in activation of the endothelium, production of inflammatory cytokines like
TNFα, promote circulation of abnormally high base-line leukocyte counts [146], as
well as increased production of reactive oxygen species [153, 66], consistent with what
is found in humans with sickle cell disease.
The presence of elevated inflammatory factors, activation of vascular endothelial
cells, and increased monocyte adhesion and emigration into the vascular wall char-
acteristic of vascular injury and inflammation in sickle cell disease are also known
to be critical initiating events in the development of several vascular remodeling
pathologies, such as atherosclerosis [151, 89, 37, 17]. During the progression of vas-
cular remodeling diseases systemic inflammation and monocyte infiltration into the
sub-endothelial space stimulate production and secretion of cathepsins, specifically
cathepsin K. Previous work by our group has shown that both TNFα and circulating
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monocytes isolated from people with sickle cell disease are sufficient to induce cathep-
sin K activity in vascular endothelial cells [68, 67], suggesting that the elevated TNFα
and increased circulating monocytes reported by others may result in the substantially
elevated levels of arterial cathepsin K reported in this study (Fig 3, 11). In addition to
increased cathepsin activity, matrix metalloproteinase (MMPs), specifically MMP-2
and MMP-9, have also been implicated as mediators of vascular remodeling diseases
due to increased MMP activity at sights of arterial remodeling [71, 112], and their
activation in response to TNFα in atherosclerosis [52, 151]. However, cathepsin K
is regarded as a principle initiators of arterial remodeling pathologies due to their
extreme potency for hydrolyzing both insoluble elastin and collagen I [80, 59, 44], as
well as their activation in response to hemodynamic shear stress [111].
Although elevated inflammatory cytokines and recruitment of circulating white
blood cells aid in the early development of vascular remodeling, hemodynamic shear
stress has been regarded for decades as the initiating perturbation to the vasculature
to initiate pathological remodeling [73, 152, 49, 96, 31]. Normally, changes in arterial
blood flow are detected by the mechanosensitive endothelial cells that line the luminal
of the vessel alter vascular tone and maintain a stable wall shear stress. However,
sections of the vascular tree that have sharp bends or bifurcations inexorably develop
regions of disturbed blood flow, which stimulate pro-remodeling cellular responses
in the vascular wall. Specifically, cathepsin K is upregulated at these sites of the
disturbed flow, which is secreted into the arterial wall and degrades the elastin fibers
that provide mechanical support and function to the arterial wall.
Insoluble elastin fibers in the arterial wall provide the restoring force necessary to
propagate blood through large vessels and throughout the body, as well as provide
a resistance to blood pressure; loss of elastin integrity leads to reduced blood per-
fusion and increased risk of vessel rupture, as observed in aortic aneurisms [81, 12].
In addition to the changes in vessel biomechanics, elastin degradation also alters the
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phenotypes of the component cells within the arterial wall. Loss of elastin integrity
within the medial layer of the artery induces resident smooth muscle cells to revert
from a quiescent, contractile state, to a migratory, proliferative state whereby they
invade the sub-endothelial space resulting leading to luminal narrowing, further dis-
ruption of blood flow, as well as secretion of cathepsin K, ultimately generating a
pro-remodeling feed-forward system.
In sickle cell disease, it is believed that regions of disturbed blood flow are not
only limited to specific geometries, as is seen with atherosclerosis, but instead can
form spontaneously throughout the vascular tree. Sickle red blood cells are inherently
adhesive to themselves, other circulating white blood cells, and the vascular endothe-
lium allowing the spontaneous formation of aggregations along luminal side of the
vessel wall [61, 64, 20, 40]. While aggregations of circulating red cells are the root of
the vasooclusive crises described above, they are not limited to the microvasculature;
there is growing evidence that cellular aggregations can spontaneously form in larger
vessels resulting in disturbed blood flow [11]. The capacity of the sickle vasculature
to spontaneously develop regions of disturbed flow, combined with the ubiquitous
presence of elevated TNFα and enhanced mobilization of circulating monocyte, could
explain why people with sickle cell disease develop vascular remodeling lesions in ves-
sels, such as the middle cerebral artery, where other remodeling pathologies are rarely
seen.
Repetitive sickling of the red blood cell results in premature hemolysis, releas-
ing free heme, the oxygen carrying core of hemoglobin, into the blood plasma [133].
Increased plasma levels of heme scavenge nitric oxide, a powerful vasodilator pro-
duced by endothelial cells, crippling arteries capacity to dilate and increase blood
profusion. Loss of available nitric oxide by heme scavenging has been hypothesized
to specifically hinder vasodilation in the cerebral arteries, not only inhibiting oxygen
profusion to the brain, but also may be one of the initiating stages of stroke lesion
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development. It is plausible that inhibition of vasodilation could significantly im-
pair endothelial cells capacity to restore hemodynamic shear stress in the presence
of a spontaneous red cell aggregation, thereby leading to the premature initiation of
arterial remodeling cellular programs and accelerating progression of vascular lesion
development. Additionally, loss of nitric oxide has been speculated to result in a
hyper sensitivity of the sickle vasculature to vasoconstrictors, such as angiotensin II
[9]. Increased angiotensin II signaling is known to increase arterial restructuring akin
to what is observed in sickle cell disease, with increased hypertension resulting from
intima-media thickening. Furthermore, angiotensin II activates the JNK signaling
pathway, which we have shown here to be strongly implicated in arterial remodeling
in sickle cell disease (Fig 6-12- 6-14). Therefore, the findings of this study implicate
that JNK signaling may represent a significant integration point for the induction of
cerebral vascular remodeling in sickle cell disease. We have shown previously that
JNK signaling is critical for TNFα induction of cathepsin K in vascular endothelial
cells [67, 68], which may contribute to elastin fragmentation stimulating in vivo lead-
ing to stimulation of arterial remodeling. Simultaneously, increased reactive oxygen
stress may induce angiotensin II-induced signaling of JNK to promote smooth muscle
cells proliferation and intimal-medial thickening, and exacerbating arterial remodel-
ing. However, inhibition of JNK signaling, as we have seen in this study reduces
cathepsin K activity (Fig 6-13, 6-14), and may also inhibit angiotensin II signaling,
thereby mitigating pro-remodeling signals in the arterial wall two-fold.
The development of the Townes sickle transgenic animal model has been an in-
valuable tool for elucidating the underlying cellular mechanisms that result in the
multitude of pathologies and syndromes associated with human sickle cell disease.
However, the vasculopathy responsible for development of stroke in sickle cell disease
remains largely under-characterized in the transgenic mouse model, hindering robust
mechanistic descriptions of how it is initiated and progresses in humans. Townes sickle
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transgenic animals have a markedly shorter life span, and are vulnerable to asymp-
tomatic, idiopathic mortality[16, 103]. In this study we are the first to identify that
sickle transgenic animals develop substantial remodeling of the carotid arteries, nar-
rowing of the cerebral arteries (Fig 6-4- 6-7), and potentially development of stroke
lesions throughout the brain (Fig 6-9), implicating the development of cerebrovascu-
lar disease and stroke may also result in the observed decrease in animal survivability.
Furthermore, our work here has identified JNK as a potential in vivo integration point
for the development of severe arterial remodeling in the carotid and middle cerebral
arteries of sickle mice, which has strong implications towards development of pharma-
ceutical prophylactics for stroke development. Although regular blood transfusions
have been shown to mitigate the risk of stroke in young children with sickle cell dis-
ease, the chronic transfusions needed carry significant and life-threatening risks of
alloimmunity, iron over load, and infection [4, 41, 133]; however, this remains the
only available therapy as there are currently no pharmaceutical treatment options
available. By identifying other mechanistic pathways by which cathepsin activity is
regulated by the hemodynamic and inflammatory environment of sickle cell disease,
these may present new therapeutic targets for reduction in the risk of death for young





The work presented in this thesis focused on developing a more complete under-
standing of the initiation and progression of vascular dysfunction leading to stroke
in young children with sickle cell disease. Based on the strong histological similar-
ities between sickle cell vasculopathy and other progressive cardiovascular diseases,
specifically rapid remodeling of the cerebral and carotid arteries, we hypothesized
that the unique circulatory milieu of sickle cell disease may stimulate upregulation of
cathepsins, which have been linked to initiation and progression of arterial remodel-
ing. To achieve this, we systematically investigated how the large artery endothelial
cells integrated the complex inflammatory signals unique to circulatory environment
of sickle cell disease.
As discussed previously and confirmed by our studies, people with sickle cell dis-
ease have chronically elevated serum levels of TNFα, resulting in a perpetual ac-
tivation of the vascular endothelium. My work demonstrates that TNFα alone is
sufficient to induce high levels of cathepsin K and V in large artery endothelial cells,
both of which are known to be up-regulated in early arterial remodeling pathologies.
Furthermore, I have shown that the circulating monocytes isolated from people with
sickle cell disease are more adherent than normal monocytes, and have the unique
ability themselves to induce and increase cathepsin K and V, respectively; monocyte-
endothelial cell interactions are also argued to be one of the key initiating steps of
arterial remodeling. Therefore, the findings from this thesis support the idea that
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sickle cell disease promotes and sustains a pro-arterial remodeling environment me-
diated by elevated cathepsin activation and expression. More specifically, however,
I have also identified that both TNFα and sickle monocyte adhesion up-regulate
cathepsins K and V through the JNK-c-Jun signaling cascade. Taken together, these
data identify three unique targets for novel therapeutic intervention: management of
chronic inflammation, direct inhibition of cathepsin K and V activities, and inhibition
of JNK/c-Jun activation and signaling.
There is a well-established correlation between the vulnerability of arteries to re-
modeling, and the magnitude and direction of hemodynamic wall shear stress; specifi-
cally, high shear stress is protective from pathological remodeling, and low, oscillatory
shear stress promotes remodeling. Furthermore, cathepsin K and V are both known
to be up-regulated by the same low, oscillatory shear stress that promotes arterial
remodeling. Therefore, given stroke in sickle cell disease results from rapid arterial
remodeling, combined with the implication that the remodeling is a result of inflam-
matory up-regulate cathepsin K and V, it was important that our work also take into
consideration the contributions of biomechanical shear stress. Through use of a cone-
and-plate shear stress bioreactor, we were capable of actuating physiological shear
stress waveforms characteristic of arterial regions protected or vulnerable to remodel-
ing. Of particular note was our conclusion that vasoprotective shear stress is sufficient
to significantly reduce active cathepsin K in large artery endothelial cells, even in the
presence of TNFα; similarly, pro-remodeling shear stress was able to induce cathepsin
K independent of TNFα stimulation. Furthermore, we identified regulation of NFκB
expression in arterial endothelial cells as the crucial intracellular signaling cascade
responsible for biomechanical regulation of cathepsin K activity. Not only do the
findings here serve to directly identify NFκB as another novel therapeutic target,
but my work also contributes to a more complete understanding of the fundamental
regulation of the systemic and cellular mechanisms that may be responsible for the
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generation of arterial occlusion leading to stroke in sickle cell disease.
In an effort to expand these findings into a test system that would allow for greater
translation into clinical development of therapies for stroke in sickle cell disease, we
investigated the effect of systemic inhibition of JNK signaling in the Townes sickle
transgenic mouse model. In our in vivo studies, we identified that sickle cell disease
promotes remodeling of the carotid and cerebral arteries, as evidenced by increased
elastin fragmentation, delamination, and luminal narrowing, compared to both AA
and AS mice. Sickle cell disease also resulted in substantially higher cathepsin K ex-
pression in the carotid arteries, suggesting that elevated cathepsin K expression and
activity may be linked to the increased incidence of elastin degradation. Additionally,
mice with sickle cell disease also presented high neuronal cell death and the devel-
opment of potential stroke lesions identified by MRI scans. However, administration
of the JNK inhibitor SP600125 had the notable result reducing cathepsin expression
and activity, as well as reducing the incidence of elastin fragmentation. While pre-
liminary, these results strongly support targeted JNK inhibition as viable therapeutic
target for the inhibition of cathepsin K and prevention of sickle cell disease related
vasculopathy.
The cumulative findings of this doctoral thesis provide a novel foundation for
understanding the dynamic interactions between the unique inflammatory and hemo-
dynamic environment in sickle cell disease, and their contributions to promoting the
formation of stroke in young children. Through the use in vitro bioreactor systems,
my work has identified multiple new therapeutic targets and begun to test their va-
lidity in in vivo animal models. However, there remains a large body of work yet to
be completed with regards to more completely understanding the hemodynamic en-
vironment of the cerebral vasculature, and its potential effect on cathepsin-mediated
arterial remodeling, the incorporation of more advanced analysis techniques for more
complete understanding of the biomolecular networks involved, and development and
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implementation of more advanced in vitro culture technologies.
7.2 Exploration of cathepsin K activation in cerebral vas-
culature through in vitro actuation of cerebral blood
flow
Work discussed in this thesis has underscored the critical regulatory nature of hemo-
dynamics in regulating the structure and function of the vasculature, and how al-
terations to wall shear stress can generate powerful feed-forward loops that lead to
pathological arterial remodeling, potentially leading to stroke in children with sickle
cell disease. However, the sickle mutation also significantly changes the bulk bio-
physical properties of whole blood. The altered red blood cell morphology caused
by sickling, combined with aberrant aggregation of red cells to each other, circulat-
ing white blood cells, and the arterial wall result in changes in blood viscosity in
non-intuitive ways, potentially leading to unique hemodynamic shear stresses that
develop through the vessels known clinically to be vulnerable to stroke formation.
By analyzing whole blood obtained from donors with sickle cell disease, it would be
possible to obtain key, bulk physical properties, such as viscosity, that could then be
incorporated into a computational fluid dynamic model of the vasculature to directly
calculate pathophysiologically relevant wall shear stress unique to sickle cell disease at
several points along the vascular tree. Since alterations in hemodynamic shear stress
have long been regarded as a key initiating factor of pathological arterial remodeling,
it would be highly advantageous to incorporate the unique biophysical properties of
the hemodynamic environment in the study of sickle cell related vasculopathy.
Work done by the Veneziani group at Emory University has developed advanced
computational tools to recreate three-dimensional, arterial geometries through anal-
ysis of magnetic resonance angiography (MRA) images [6, 109]. The reconstructed
geometry can then be imported into novel computational fluid dynamic software, also
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developed by the Veneziani group, that develops a high resolution, finite element anal-
ysis (FEA) model of the vasculature that can be used to calculate multiple system
values, including wall shear stress, blood pressure, and multi-dimensional flow profiles
with high spatiotemporal fidelity based on a small number of user-defined boundary
and initial conditions. The ability to analyze human arterial geometries is of consid-
erable benefit as it will allow for an unprecedented level of comparison of the changes
in the circulatory and hemodynamic environment in sickle cell disease compared to
people with normal hemoglobin, especially in the regions of the cerebral vasculature
where little is known about hemodynamic flow profiles. Use of advanced computa-
tional fluid analysis can also be easily paired with the in vitro cone-and-plate shear
system used in our lab. Derivation of the time-dependent wall shear stress could be
input into the shear bioreactor and actuated on arterial endothelial cell cultures with
the for millisecond temporal accuracy. Additionally, this technology could then be
used to analyze unique differences in vasculature and hemodynamics between people
without sickle cell disease, people with no history of sickle cell related stroke, those
at risk for sickle related stroke, and those with a history of stroke. Currently, there
the only predictive method for identification of stroke risk in children with sickle cell
disease is transcranial Doppler ultrasound (TCD), in high risk is defined as blood ve-
locities greater than 200cm/s [3, 60, 2]. While non-invasive and useful for ascertaining
relative risk of stroke, TCD generally does not have sufficient resolution to evaluate
the severity or location of stroke lesions. However, more complete mechanistic inves-
tigations into potential differences in vascular geometry, and biophysical properties
of blood from a wide range of patients with varying stroke risk could lead to novel
discoveries and more accurate predictive and preventative methods. Additionally,
bi-directional investigations between computation analysis and in vitro bioreactor
experiments would also allow for novel retrospective and prospective clinical stud-
ies. MRAs taken from patients with identified sites of arterial remodeling, leading
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to stroke, could be analyzed through computational analysis to determine hemody-
namic shear profiles near the site of occlusion, actuate those shear stresses on arterial
endothelial cells, and quantify the resulting changes in cathepsin activity, and intra-
cellular kinases which could be used as novel predictive biomarkers for early detection
of arterial remodeling. Correlation of cathepsin upregulation activity, in conjunction
with up-stream kinase signals, with severity of stroke progression could also lead to
the development of novel preventative measures, by which physicians could more ac-
curately assess the risk a given patient has for the development of stroke as well as
provide more accurate and personalized treatment options.
7.3 Development of high resolution imaging of vascular re-
modeling proximal to stroke lesions in sickle transgenic
mice
The development of the sickle transgenic mouse with humanized hemoglobin has been
a substantial boon to the entire field dedicated to understanding the in vivo repercus-
sions of sickle cell disease; however many of the human pathologies associated with
sickle cell disease are not yet characterized in the animal model. This study was not
only the first to describe the development of cathepsin-mediated vascular remodeling
in the carotid and cerebral arteries in sickle transgenic animals comparable to what
is observed in humans, but was also the first study to identify the potential develop-
ment of stroke lesions. While the findings from this study are extremely promising for
developing a more complete, mechanistic understanding of the initiation, progression,
and regulation of sickle mediated arterial remodeling, additional investigations must
be completed.
Stroke lesions were identified in these studies through the use of high-resolution
MRI scanning to identify areas of the brain that developed a dark appearance on
the image, indicative of poor blood profusion and possible stroke development. The
brains should then be histologically processed to identify morphological changes in
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the cerebral arteries around the anomalous regions identified by MRI. By cross vali-
dating the MRI imaging with histological morphology, it could be more conclusively
stated how the stroke lesions developed, better characterize the type of lesion (hemor-
rhagic versus ischemic), and characterize similarities between the pathology of stroke
in mice compared to what is known about sickle cell mediated stroke in human pa-
tients. However, this process is laborious and would require an extremely high level of
histological proficiency to successfully reconstruction of the entire brain vasculature
for a 1:1 comparison to the MRI scans. Additionally, the high degree of tortuosity of
the cerebral vessels would make it difficult to predict the axis on which to conduct
the histological slices; based on which surgical axis the vessel is oriented; sectioning
along the incorrect axis significantly impair the ability to identify evidence of arterial
remodeling and other morphological changes in and around the stroke lesion. To ad-
dress these complications and limitations, one could use plastination of the cerebral
vessels to gain high resolution reconstruction of changes in the arterial network as a
result of sickle cell disease.
The cerebral vessels in mice are substantially smaller than those found in humans,
and therefore it is difficult to obtain high resolution, structural images of the vessels
using traditional, non-invasive techniques such as MRA or angiography. However, mi-
cro computed tomography (µCT) is capable of generating high resolution imaging of
internal vasculature of small animals, such as mice. Perfusion of a liquid plastic poly-
mer throughout the vasculature of the animal perimortem allows for the delivery of a
contrast agent that is detected by the µCT imager; the plastic solidifies shortly after
profusion preventing diffusion or weakening of the contrast signal. Three-dimensional
reconstructions of the cerebral vasculature can be analyzed on a population level to
identify systemic changes in the profusion of the plastic that could indicate regions of
arterial narrowing or occlusion in sickle animals. The plastinated brains could then be
imaged by MRI to determine if potential stroke lesions co-localize with the identified
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regions of arterial narrowing. Additionally, the reconstructed µCT scans could also
be used to generate finite element models of cerebral blood flow in the transgenic an-
imal models, as we discussed previously. Analysis of blood velocity, wall shear stress,
and blood viscosity and generation of predictive models for the development of stroke
lesions in the transgenic animals, compared to human data could further validate the
use of the Townes mouse model for the study of sickle cell related vascular disease.
7.4 in vivo investigation of specific cathepsin K inhibitors
as novel drug therapeutics for prevention of stroke in
sickle cell disease
The finding sickle transgenic animals had substantially elevated cathepsin K expres-
sion in the carotid arteries, which co-localized with the increased degradation of the
elastin fibers within the arterial wall strongly supports the hypothesis that sickle cell
mediated arterial remodeling is propagated, to a significant level, by the pathological
activation of cathepsin K. In this study, inhibition of JNK was shown to be effective
in decreasing cathepsin K expression and activity in the sickle vasculature, as well
as preventing arterial degradation, based on our findings from in vitro studies, JNK
signaling is strongly implicated in activation of cathepsin K in vascular endothelial
cells. However, JNK signaling is critical in several cellular responses to inflammation,
damage, and infection; therefore, systemic inhibition of JNK signaling may have sub-
stantial side effects in humans, although none were observed in the mice. However,
direct, targeted inhibition of cathepsin K could prove to be highly effective in the
prevention of sickle cell related vasculopathy. Odanacatib is a highly specific cathep-
sin K specific inhibitor that is currently undergoing FDA approval for the treatment
of osteoporosis and bone metastasis[45, 33]. Initiation of animal trials for odanacatib
would not only provide additional verification that pathological cathepsin K activa-
tion in sickle cell disease leads to increased vascular remodeling, but may also identify
odanacatib as the first ever drug for the safe treatment and prevention of vascular
102
remodeling and potentially stroke development in sickle cell disease.
7.5 Application of systems biology for analysis of hetero-
geneity of vascular pathology sickle cell disease
In conjunction with the influence of hemodynamic shear stress initiation of arterial
remodeling, findings from my in vitro studies implicate chronic exposure to inflam-
matory cytokines, such as TNFα, as well as increased monocyte-endothelial cell in-
teractions, are potent activators of cathepsin activity in arterial endothelial cells,
particularly in sickle cell vasculopathy. However, while all people who suffer from
sickle cell disease possess the same genetic mutation, clinical case studies of multiple
sickle cell pathologies report a wide dichotomy of severity among different patients;
sickle cell disease increases risk of stroke in young children over 200-fold, but stroke
is only reported in about 10% of affected children. Some studies attribute decreased
severity in some patients due to a natural preservation of the expression of fetal
hemoglobin (HbF). Similar to -globin, HbF forms a tetramer with β-globin molecules
to form a complete hemoglobin molecule, however, human expression of HbF is usu-
ally silenced and replaced by -globin within weeks after birth. However, some people
with sickle cell disease retain significant levels of HbF expression well into adulthood,
effectively diluting the level of expressed sickle hemoglobin. Reactivation of HbF
is also the hypothesized mode of action of hydroxyurea, the only pharmacological
treatment shown to be effective at ameliorating complications of sickle cell disease;
however, hydroxyurea alone has not been effective at reducing the incidence of strokes
in young children.
Research by Park et al. and others [101, 15] successfully demonstrated that sys-
tems biology can be applied to generate predictive models of disease outcomes based
on analysis of a variety of biomarkers and signaling kinases. Furthermore, systems
biology is unique in its ability to process extremely large data sets to determine which
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inputs co-vary with known pathologies as highly efficient way to parse out how com-
plex systems are regulated and influence clinical outcomes in otherwise unforeseen
ways. In sickle cell disease, patients can have variations in serum levels of TNFα and
other inflammatory cytokines, numbers of circulating monocytes, relative cathepsin
activity levels, red blood cell population composition, fetal hemoglobin content, and
a variety of other factors that could themselves, or in conjunction with other fac-
tors, modulate a person’s susceptibility to comorbidities, such as stroke development.
Many of these values may also vary depending if the person is experiencing a vasooc-
clusive crisis. The number of variables that can contribute to sickle cell pathologies
make systematic investigation and development of comprehensive, mechanistic expla-
nations for the development and progression of known pathologies difficult.
Sickle cell disease can be thought of as a disease of compounding unity: a mutation
in nucleotide of one gene that results in one amino acid substitution in one protein
expressed in only one type of cell. Since the cells most directly affected by the sickle
mutation are circulating red blood cells, every organ system in the body is negatively
effected in an appreciable, and sometimes, deadly ways. However, investigations into
sickle cell disease often operate in relative isolation due to somewhat arbitrary divi-
sions; it is rare to see investigations on a multi system scale. This tendency towards
isolative investigation is an artifact of needing to reduce the number of variables in
the system, but the resulting assumptions preclude the possibility that complications
from one sickle pathology could have a significant impact on other pathologies. Using
a systems biology approach, it would be possible to use efficiently and accurately
quantify hundreds, maybe thousands, of data points across multiple cell and tissue
types.
Chronic inflammation is a serious syndrome associated with sickle cell disease,
and has been implicated here as an initiating factor in arterial vasculopathy and
stroke development in young children. However the perpetuation of inflammation
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in sickle cell disease is contested by several investigators, some hypothesizing that
chronic inflammation is the result of pathological adherence of red blood cells to
the vascular endothelium, resulting in systemic endothelial damage and dysfunction.
Others contend that chronic inflammation may result from ischemic-profusion injury
and exposure to reactive oxygen species generated by repetitive vasooclusive crises
in the microvasculature. The work presented here, and research conducted by others
[67, 114, 40], indicate that circulating monocytes in sickle cell disease are patholog-
ically activated to be more adherent to the endothelium and secrete 300% higher
amounts of TNFα [14]. It is likely that there exists one single event that, alone,
generates and propagates the chronic inflammatory environment in sickle cell disease,
but expansion of experimental designs to incorporate multiple cell types stimulated
with different chemical and biophysical conditions would allow for the generation of
a more robust and physiologically relevant in vitro model system. Advances in mul-
tiplex kinase, cytokine, protein, and genetic assays allow for thousands of different
biomolecules to be assayed and quantified simultaneously, resulting in the generation
of a comprehensive molecular networks. Use of similar experimental techniques has
shown to be effective in the study of endometriosis, another inflammatory disease
characterized by heterogeneity in system presentation and severity, as well as vari-
ability in clinical outcomes. Researchers were capable of precisely identifying not only
which immune cells significantly influence the severity of endometrial lesion growth
in an in vivo animal model, but also which specific signaling pathways within those
immune cells could most effectively be targeted for maximal therapeutic effect us-




CODE FOR ACTUATION OF PHYSIOLOGICAL
WAVEFORMS IN CONE-AND-PLATE BIOREACTOR
1 PROGRAM
2 ’Program 0
3 ’TODO: ed i t your program here
4 CLEAR
5 dr ive on A
6 dr iv e on B
7 dr iv e on C
8 dr iv e on D
9 dr iv e on V
10 dr ive on X
11 dr ive on Y




16 #DEFINE timecount LV0
17 #DEFINE sy s c l o c k P6916
18
19 sy s c l o ck = 0
20 timecount = 0
21
106
22 whi l e ( timecount <100000)
23
24 sy s c l o ck = 0
25
26
27 whi l e ( sy sc l ock <30)
28 JOG ACC A 100 B100 V100 X100 C80 D80 Y80 Z80
29 JOG VEL A2.77 B2 .77 V2.77 X2.77 C2 D2 Y2 Z2
30 JOG FWD A B C D V X Y Z
31 wend
32
33 whi l e ( ( s y s c l o ck =30) OR ( sysc lock >30) AND ( sysc lock <60) )
34 JOG ACC A110 B110 V110 X110
35 JOG DEC C91 D91 Y91 Z91
36 JOG VEL A2.77 B2 .77 V2.77 X2.77
37 JOG VEL C0 D0 Y0 Z0
38 JOG FWD A B V X
39 JOG FWD C D Y Z
40 wend
41
42 whi l e ( ( s y s c l o ck =60) OR ( sysc lock >60) AND ( sysc lock <95) )
43 JOG ACC A110 B110 V110 X110
44 JOG ACC C125 D125 Y125 Z125
45 JOG VEL A2.77 B2 .77 V2.77 X2.77
46 JOG VEL C4.15 D4.15 Y4.15 Z4 .15
47 JOG FWD A B V X




51 whi l e ( ( s y s c l o ck =95) OR ( sysc lock >95) AND ( sysc lock <115) )
52 JOG ACC A110 B110 V110 X110
53 JOG DEC C101 D101 Y101 Z101
54 JOG VEL A2.77 B2 .77 V2.77 X2.77
55 JOG VEL C0 D0 Y0 Z0
56 JOG FWD A B V X
57 JOG REV C D Y Z
58 wend
59
60 whi l e ( ( s y s c l o ck =115) OR ( sysc lock >115) AND ( sysc lock <145) )
61 JOG ACC A115 B115 V115 X115
62 JOG DEC C101 D101 Y101 Z101
63 JOG VEL A8.33 B8 .33 V8.33 X8.33
64 JOG VEL C0 D0 Y0 Z0
65 JOG FWD A B C D V X Y Z
66 wend
67
68 whi l e ( ( s y s c l o ck =145) OR ( sysc lock >145) AND ( sysc lock <170) )
69 JOG ACC A115 B115 V115 X115
70 JOG ACC C58 D58 Y58 Z58
71 JOG VEL A8.33 B8 .33 V8.33 X8.33
72 JOG VEL A0.78 B0 .78 Y0.78 Z0 .78
73 JOG FWD A B V X




77 whi l e ( ( s y s c l o ck =170) OR ( sysc lock >170) AND ( sysc lock <195) )
78 JOG ACC A115 B115 V115 X115
79 JOG DEC C30 D30 Y30 Z30
80 JOG VEL A8.33 B8 .33 V8.33 X8.33 C0.01 D0.01 Y0.01 Z0 .01
81 JOG FWD A B V X
82 JOG FWD C D Y Z
83 wend
84
85 whi l e ( ( s y s c l o ck =195) OR ( sysc lock >195) AND ( sysc lock <200) )
86 JOG DEC A26 B26 V26 X26
87 JOG DEC C30 D30 Y30 Z30
88 JOG VEL A3.5 B3 . 5 V3. 5 X3. 5
89 JOG REV C0.01 D0.01 Y0.01 Z0 .01
90 JOG FWD A B V X
91 JOG FWD C D Y Z
92 wend
93
94 whi l e ( ( s y s c l o ck =220) OR ( sysc lock >200) AND ( sysc lock <260) )
95 JOG DEC A26 B26 V26 X26
96 JOG ACC C19 D19 Y19 Z19
97 JOG VEL A3.5 B3 . 5 V3. 5 X3. 5 C0.97 D0.97 Y0.97 Z0 .97
98 JOG FWD A B V X
99 JOG REV C D Y Z
100 wend
101
102 whi l e ( ( s y s c l o ck =260) OR ( sysc l ock >260) AND ( sysc lock <305) )
109
103 JOG DEC A26 B26 V26 X26
104 JOG ACC C27 D27 Y27 Z27
105 JOG VEL A3.5 B3 . 5 V3. 5 X3. 5
106 JOG VEL C0 D0 Y0 Z0
107 JOG FWD A B V X
108 JOG REV C D Y Z
109 wend
110
111 whi l e ( ( s y s c l o ck =305) OR ( sysc l ock >305) AND ( sysc lock <380) )
112 JOG DEC A26 B26 V26 X26
113 JOG ACC C13 D13 Y13 Z13
114 JOG VEL A3.5 B3 . 5 V3. 5 X3. 5
115 JOG VEL C0.83 D0.83 Y0.83 Z0 .83
116 JOG FWD A B V X
117 JOG FWD C D Y Z
118 wend
119
120 whi l e ( ( s y s c l o ck =380) OR ( sysc l ock >380) AND ( sysc lock <400) )
121 JOG DEC A26 B26 V26 X26
122 JOG DEC C11 D11 Y11 Z11
123 JOG VEL A3.5 B3 . 5 V3. 5 X3. 5
124 JOG VEL C0 D0 Y0 Z0
125 JOG FWD A B V X
126 JOG FWD C D Y Z
127 wend
128
129 whi l e ( ( s y s c l o ck =400) OR ( sysc l ock >400) AND ( sysc lock <465) )
110
130 JOG ACC A25 B25 V25 X25
131 JOG DEC C11 D11 Y11 Z11
132 JOG VEL A3.82 B3 .82 V3.82 X3.82
133 JOG VEL C0 D0 Y0 Z0
134 JOG FWD A B V X
135 JOG FWD C D Y Z
136 wend
137
138 whi l e ( ( s y s c l o ck =465) OR ( sysc l ock >465) AND ( sysc lock <510) )
139 JOG ACC A25 B25 V25 X25
140 JOG ACC C3 D3 Y3 Z3
141 JOG VEL A3.82 B3 .82 V3.82 X3.82
142 JOG VEL C0 . 5 D0. 5 Y0. 5 Z0 . 5
143 JOG FWD A B V X
144 JOG FWD C D Y Z
145 wend
146
147 whi l e ( ( s y s c l o ck =510) OR ( sysc l ock >510) AND ( sysc lock <610) )
148 JOG ACC A16 B16 V16 X16
149 JOG ACC C3 D3 Y3 Z3
150 JOG VEL A3.02 B3 .02 V3.02 X3.02
151 JOG VEL C0 . 5 D0. 5 Y0. 5 Z0 . 5
152 JOG FWD A B V X
153 JOG FWD C D Y Z
154 wend
155
156 whi l e ( ( s y s c l o ck =610) OR ( sysc l ock >610) AND ( sysc lock <745) )
111
157 JOG DEC A4 B4 V4 X4
158 JOG ACC C3 D3 Y3 Z3
159 JOG VEL A2.63 B2 .63 V2.63 X2.63
160 JOG VEL C0 . 5 D0. 5 Y0. 5 Z0 . 5
161 JOG FWD A B V X
162 JOG FWD C D Y Z
163 wend
164
165 whi l e ( ( s y s c l o ck =745) OR ( sysc l ock >745) AND ( sysc lock <975) )
166 JOG DEC A4 B4 V4 X4
167 JOG DEC C1.9 D1. 9 Y1. 9 Z1 . 9
168 JOG VEL A2.63 B2 .63 V2.63 X2.63
169 JOG VEL C0.17 D0.17 Y0.17 Z0 .17
170 JOG FWD A B V X
171 JOG FWD C D Y Z
172 wend
173
174 timecount = timecount +1
175
176 print ”Timecount=” , timecount
177 print ” Sysc lock=” , s y s c l o ck
178 wend
179
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[86] Malavé, I., Perdomo, Y., Escalona, E., Rodriguez, E., Anchustegui,
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I., Matthias, R., Mönnig, G., Haverkamp, W., Breithardt, G.,
Schmahl, W., Peters, C., and Reinheckel, T., “Dilated cardiomyopa-
thy in mice deficient for the lysosomal cysteine peptidase cathepsin L.,” Proc
Natl Acad Sci USA, vol. 99, pp. 6234–6239, Apr. 2002.
[129] Sukhova, G. K., Shi, G. P., Simon, D. I., Chapman, H. A., and Libby,
P., “Expression of the elastolytic cathepsins S and K in human atheroma and
regulation of their production in smooth muscle cells.,” J Clin Invest, vol. 102,
pp. 576–583, Aug. 1998.
[130] Sumoza, A., de Bisotti, R., Sumoza, D., and Fairbanks, V., “Hydrox-
yurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).,” Am
J Hematol, vol. 71, pp. 161–165, Nov. 2002.
[131] Sun, J., Sukhova, G. K., Zhang, J., Chen, H., Sjoberg, S., Libby, P.,
Xia, M., Xiong, N., Gelb, B. D., and Shi, G. P., “Cathepsin K Deficiency
Reduces Elastase Perfusion-Induced Abdominal Aortic Aneurysms in Mice,”
Arterioscler Thromb Vasc Biol, vol. 32, pp. 15–23, Dec. 2011.
[132] Swirski, F. K., Libby, P., Aikawa, E., Alcaide, P., Luscinskas,
F. W., Weissleder, R., and Pittet, M. J., “Ly-6Chi monocytes dominate
hypercholesterolemia-associated monocytosis and give rise to macrophages in
atheromata,” J Clin Invest, vol. 117, pp. 195–205, Jan. 2007.
[133] Switzer, J. A., Hess, D. C., Nichols, F. T., and Adams, R. J., “Patho-
physiology and treatment of stroke in sickle-cell disease: present and future,”
Lancet neurology, vol. 5, pp. 501–512, June 2006.
[134] Taleb, S., Cancello, R., Poitou, C., Rouault, C., Sellam, P., Levy,
P., Bouillot, J.-L., Coussieu, C., Basdevant, A., Guerre-Millo, M.,
125
Lacasa, D., and Clement, K., “Weight loss reduces adipose tissue cathepsin
S and its circulating levels in morbidly obese women.,” J. Clin. Endocrinol.
Metab., vol. 91, pp. 1042–1047, Mar. 2006.
[135] Tedgui, A. andMallat, Z., “Anti-Inflammatory Mechanisms in the Vascular
Wall,” Circ Res, vol. 88, pp. 877–887, May 2001.
[136] Thoma, B., Grell, M., Pfizenmaier, K., and Scheurich, P., “Identi-
fication of a 60-kD tumor necrosis factor (TNF) receptor as the major signal
transducing component in TNF responses,” J Exp Med, vol. 172, pp. 1019–1023,
Oct. 1990.
[137] Tolosa, E., Li, W., Yasuda, Y., Wienhold, W., Denzin, L. K.,
Lautwein, A., Driessen, C., Schnorrer, P., Weber, E., Stevanovic,
S., Kurek, R., Melms, A., and Bromme, D., “Cathepsin V is involved in
the degradation of invariant chain in human thymus and is overexpressed in
myasthenia gravis,” J Clin Invest, vol. 112, pp. 517–526, Aug. 2003.
[138] Tuohy, A. M., McKie, V., Manci, E. A., and Adams, R. J., “Internal
carotid artery occlusion in a child with sickle cell disease: case report and
immunohistochemical study.,” J. Pediatr. Hematol. Oncol., vol. 19, pp. 455–
458, Aug. 1997.
[139] Turk, B., Turk, V., and Turk, D., “Structural and functional aspects of
papain-like cysteine proteinases and their protein inhibitors.,” Biological Chem-
istry, vol. 378, pp. 141–150, Feb. 1997.
[140] Turk, B., Turk, D., and Salvesen, G. S., “Regulating cysteine protease
activity: essential role of protease inhibitors as guardians and regulators.,”
Curr. Pharm. Des., vol. 8, no. 18, pp. 1623–1637, 2002.
[141] Turk, B., Turk, D., and Turk, V., “Lysosomal cysteine proteases: more
than scavengers,” Biochimica et Biophysica Acta (BBA) - Protein Structure
and Molecular Enzymology, vol. 1477, pp. 98–111, Mar. 2000.
[142] Venketasubramanian, N., Prohovnik, I., Hurlet, A., Mohr, J. P.,
and Piomelli, S., “Middle cerebral artery velocity changes during transfusion
in sickle cell anemia.,” Stroke, vol. 25, pp. 2153–2158, Nov. 1994.
[143] Verduzco, L. A. andNathan, D. G., “Sickle cell disease and stroke,” Blood,
vol. 114, pp. 5117–5125, Dec. 2009.
[144] Wang, W., “Neuropsychologic performance in school-aged children with sickle
cell disease: A report from the Cooperative Study of Sickle Cell Disease,” The
Journal of Pediatrics, vol. 139, pp. 391–397, Sept. 2001.
[145] Ware, R. E., Zimmerman, S. A., and Schultz, W. H., “Hydroxyurea as
an alternative to blood transfusions for the prevention of recurrent stroke in
children with sickle cell disease.,” Blood, vol. 94, pp. 3022–3026, Nov. 1999.
126
[146] WEST, M. S., WETHERS, D., Smith, J., STEINBERG, M., JOHN-
SON, R., MCMAHON, L., Platt, O., GILL, F., OHENEFREMPONG,
K., BRAY, G., KELLEHER, J. F., LELKIN, S., Vichinsky, E., LUBIN,
B., BANK, A., Piomelli, S., ROSSE, W., FALLETTA, J., Kinney,
T. R., LESSIN, L., Smith, J., KHAKOO, Y., SCOTT, R. B., Cas-
tro, O., REINDORF, C., DIAMOND, S., Wang, W., WILIMAS, J.,
MILNER, P., BROWN, A., Miller, S., RIEDER, R., GILLETTE, P.,
LANDE, W., Embury, S., MENTZER, W., WETHERS, D., GROVER,
R., Koshy, M., TALISHY, N., Pegelow, C., KLUG, P., STEINBERG,
M., KRAUS, A., ZARKOWSKY, H., Dampier, C., PEARSON, H.,
and RITCHEY, A. K., “Laboratory Profile of Sickle-Cell Disease - a Cross-
Sectional Analysis,” Journal of Clinical Epidemiology, vol. 45, pp. 893–909,
Aug. 1992.
[147] Wilder, C. L., Park, K.-Y., Keegan, P. M., and Platt, M. O., “Ma-
nipulating substrate and pH in zymography protocols selectively distinguishes
cathepsins K, L, S, and V activity in cells and tissues.,” Arch Biochem Biophys,
vol. 516, pp. 52–57, Dec. 2011.
[148] Yang, M., Sun, J., Zhang, T., Liu, J., Zhang, J., Shi, M. A.,
Darakhshan, F., Guerre-Millo, M., Clement, K., Gelb, B. D., Dol-
gnov, G., and Shi, G.-P., “Deficiency and inhibition of cathepsin K re-
duce body weight gain and increase glucose metabolism in mice.,” Arterioscler
Thromb Vasc Biol, vol. 28, pp. 2202–2208, Dec. 2008.
[149] Yang, M., Zhang, Y., Pan, J., Sun, J., Liu, J., Libby, P., Sukhova,
G. K., Doria, A., Katunuma, N., Peroni, O. D., Guerre-Millo, M.,
Kahn, B. B., Clement, K., and Shi, G.-P., “Cathepsin L activity controls
adipogenesis and glucose tolerance,” Nat Cell Biol, vol. 9, pp. 970–977, Aug.
2007.
[150] Yasuda, Y., Li, Z., Greenbaum, D., Bogyo, M., Weber, E., and
Brömme, D., “Cathepsin V, a novel and potent elastolytic activity expressed
in activated macrophages,” J Biol Chem, vol. 279, pp. 36761–36770, Aug. 2004.
[151] Young, J. L., Libby, P., and Schonbeck, U., “Cytokines in the pathogen-
esis of atherosclerosis,” Thromb. Haemost., vol. 88, pp. 554–567, Oct. 2002.
[152] Zarins, C. K., Giddens, D. P., Bharadvaj, B. K., Sottiurai, V. S.,
Mabon, R. F., and Glagov, S., “Carotid bifurcation atherosclerosis. Quan-
titative correlation of plaque localization with flow velocity profiles and wall
shear stress.,” Circ Res, vol. 53, pp. 502–514, Oct. 1983.
[153] Zennadi, R., Chien, A., Xu, K., Batchvarova, M., and Telen, M. J.,
“Sickle red cells induce adhesion of lymphocytes and monocytes to endothe-
lium,” Blood, vol. 112, pp. 3474–3483, Oct. 2008.
127
